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“Most problems have either many answers or no answer.  
Only a few problems have a single answer.” 
  - Edmund C. Berkeley 
  
   
ABSTRACT 
Attention-Deficit/Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder, 
affecting 5-7% of children and 2.5-5% of adults worldwide. The disorder is characterized by 
excessive and age-inappropriate symptoms of inattention, hyperactivity, and impulsivity, 
which impair everyday functioning across several settings (home, school, work). Although 
great advances have been made in ADHD research during the past decades, many questions 
remain regarding the causes and consequences of ADHD.  
ADHD is conceptualized as an early onset disorder, underpinned by varying degrees of 
neurological delay or dysfunction that may be exacerbated by environmental factors. The 
disorder is developmentally complex, and extensive comorbidity with other psychiatric and 
non-psychiatric disorders is the rule rather than the exception. In this thesis, quantitative and 
molecular genetic research designs were used to explore important and poorly understood 
questions regarding development, treatment safety, and comorbidity in ADHD, epilepsy and 
related childhood psychopathology. 
In Study 1, we addressed the question of whether perceived immaturity is related to the 
developmental course of ADHD from childhood to early adulthood. Using data from a 
longitudinal twin study, we estimated the overlap between ADHD and immaturity from ages 
8-9 to 19-20 years. Results showed that immaturity plays a small but significant role in ADHD 
in childhood and adolescence, largely due to shared genetic factors that diminish in importance 
with age. We also showed evidence for ADHD-related genetic stability across ages, and genetic 
innovation during adolescence and early adulthood. These findings may partly explain why 
some children show a decrease in ADHD symptoms from childhood to early adulthood, 
whereas others show a more persistent, chronic, disorder expression. 
In Study 2, we explore whether common genetic risk variants associated with ADHD also 
influences a broad range of related childhood psychopathology. Results suggested that genetic 
risk for ADHD, summed to a polygenic risk score (PRS), is associated with higher levels of 
neurodevelopmental, externalizing, and to a lesser extent, internalizing problems. Importantly, 
these associations could largely be attributed to a general psychopathology factor, capturing 
covariance across symptoms dimensions. These findings provide evidence for wide-spread 
genetic pleiotropy across psychiatric conditions, and support the notion that many identified 
genetic risk variants associated with ADHD are likely to non-specifically increase liability 
towards broad childhood psychiatric problems. 
In Study 3, we broaden our focus beyond psychiatric conditions to address the overlap between 
ADHD and epilepsy using a family co-aggregation design. Results from this large, population 
based cohort suggest that ADHD and epilepsy commonly co-occur and that this risk increase 
extends to family members of epilepsy patients. Quantitative genetic analyses revealed only a 
moderate genetic overlap across the disorder. These findings suggest that, although highly 
comorbid, epilepsy may be less genetically related to ADHD as compared to traditional 
neurodevelopmental disorders. 
  
In Study 4, we address the safety of ADHD pharmacological treatment in patients with a history 
of epileptic seizures. Using a within-individual comparison design to adjust for time-constant 
confounders that vary between individuals (e.g. baseline disorder severity, shared genetic 
liability), we found that ADHD medications were not associated with an increased risk of acute 
epileptic seizures. Despite long-standing concerns regarding the safety of stimulant ADHD 
medications in epilepsy patients, these findings suggest that ADHD medication treatment may 
be a safe and viable option even in patients with a seizure history.   
The main findings from this thesis suggest that ADHD is related to both later maturation and a 
wide range of comorbid psychiatric conditions, partly due to shared genetic risk factors. 
Importantly, the shared genetic liability between ADHD and related psychiatric conditions 
appears to be in part attributable to a general liability towards broad childhood 
psychopathology. In contrast, epilepsy and ADHD comorbidity seems to be less influenced by 
shared genetic factors and more strongly influenced by environmental factors not shared by 
family members. ADHD medication does however not appear to be a risk factor for acute 
epileptic seizures among individuals with a seizure history.  
Taken together, results from this thesis highlight important aspects of development and 
comorbidity in ADHD, and lends support to the hypothesis ADHD may be considered part of 
broader continuum of psychopathology that is underpinned by partly shared genetic factors. 
Based on evidence thus far, this genetic shared liability appears less strongly related to epilepsy.  
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1 INTRODUCTION 
Attention-Deficit/Hyperactivity Disorder (ADHD) is the most commonly diagnosed 
neuropsychiatric disorder among children today. On average, every classroom of 30 students 
will have 1 to 3 children with ADHD. Like all complex psychiatric conditions, ADHD is a 
multifactorial disorder, and no single risk factor is either necessary or sufficient to explain 
ADHD.1 Epidemiological and genetic research is beginning to unravel the complex nature of 
ADHD, with considerable evidence highlighting the importance of genetics in the etiology, 
development and comorbidity of ADHD. 
Despite showing strong heritability across the lifespan, ADHD is not a developmentally stable 
disorder, with some patients showing a steady decline of symptoms from childhood to 
adulthood and others showing a more persistent, chronic disorder progression.2-4 The causes 
underlying these different trajectories remain unclear, but both maturational processes and 
genetic influences have been proposed to contribute to the developmental course of ADHD.5-7 
Studying the contribution of genetic and environmental factors to the association between 
maturity and ADHD thus has the potential to improve understanding of remission and 
persistence of ADHD from childhood into adulthood.  
Beyond developmental complexity, comorbidity is a hallmark feature of ADHD.8 Growing 
evidence from genetic research suggest that widespread sharing of genetic risk across 
psychiatric conditions may partly explain this high level of comorbidity.9,10 Due to the central 
role of ADHD in childhood psychiatry, studying the influence of ADHD genetic risk on related 
psychiatric traits may provide important insights of the genetic architecture of childhood 
psychopathology.  
ADHD does not only co-occur with psychiatric conditions, but is also associated with 
neurological disorders. Among children with ADHD, 2-4% are affected by epilepsy,11,12 
whereas 10-30% of children with epilepsy have an ADHD diagnosis.13-15 Despite this, research 
on comorbid ADHD and epilepsy is limited. To complicate matters further, there are concerns 
regarding the safety of pharmacological treatment of ADHD in this patient group. Well-
powered epidemiological studies investigating the underlying causes of comorbidity, and 
treatment safety of ADHD in comorbid ADHD and epilepsy are therefore urgently needed.  
This thesis includes four studies investigating the role of shared genetic factors for maturity 
and childhood psychiatric comorbidity in ADHD, as well as etiology and treatment safety in 
comorbid ADHD and epilepsy. In order to study the role of genetic and environmental factors 
in disease associations, and to evaluate treatment safety, these studies relied on data from 
Swedish national registers and population-based cohorts, and employed various quantitative 
and molecular genetic research methods. 
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2 BACKGROUND  
2.1 ATTENTION-DEFICIT/HYPERACTIVITY DISORDER 
ADHD is a childhood onset neurodevelopmental disorder (NDD), characterized by excessive 
and age-inappropriate symptoms of inattention,  hyperactivity, and impulsivity.16 ADHD was 
first made reference to in medical literature in 1775 and further described in 1902 in the Lancet 
in a case series of children presenting with characteristic ADHD.1 The disorder shows marked 
heterogeneity at clinical, etiological, and pathophysiological levels and although given the 
same diagnosis, symptoms presentation and degree of impartment varies greatly between 
individuals with ADHD.1 To date, there are no tests or biomarkers for ADHD and diagnosis is 
made based on symptom assessment.17  
Table 2.1. Key diagnostic symptoms of ADHD 
2.1.1 Diagnostic assessment 
ADHD is classified according to two parallel diagnostic systems: The International 
Classification of Diseases and Related Health Problems (ICD),18 which is predominantly used 
in Europe, and the Diagnostic and Statistical Manual of Mental Disorders (DSM),16 which is 
predominantly used North America. In the ICD, ADHD is referred to as Hyperkinetic disorder 
(HKD). HKD requires the presence of both inattentive and hyperactive/impulsive symptoms 
across two or more settings (e.g. school and home) and tends to capture more severe cases. In 
the DSM-5 which was introduced in 2013, ADHD diagnosis can be based on the presence of 
either inattentive or hyperactive/impulsive symptoms that are inconsistent with developmental 
level and cause impairment in social and academic/occupational functioning. Unlike the ICD, 
Inattentive symptoms Hyperactivity or impulsivity symptoms 
 Does not give close attention to details or 
makes careless mistakes 
 Fidgets with or taps hands or feet, or 
squirms in seat 
 Has difficulty sustaining attention on tasks 
or play activities 
 Leaves seat in situations when staying 
seated is expected 
 Does not seem to listen when directly 
spoken to 
 Runs about or climbs when not appropriate 
(may present as feelings of restlessness in 
adolescents or adults) 
 Does not follow through on instructions and 
does not finish schoolwork, chores, or duties 
in the workplace 
 Unable to play or undertake leisure activities 
quietly 
 Has trouble organizing tasks or activities  “On the go”, acting as if “driven by a  
motor” 
 Avoids, dislikes, or is reluctant to do tasks 
that need sustained mental effort 
 Talks excessively 
 Loses things needed for tasks or activities  Blurts out answers before a question has 
been finished 
 Easily distracted  Has difficulty waiting his or her turn 
 Forgetful in daily activities  Interrupts or intrudes on others 
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the DSM-5 recognizes three subtypes of ADHD; primarily inattentive, primarily hyperactive-
impulsive, and a combined type.16 Core diagnostic symptoms of ADHD are outlined in Table 
2.1. Several changes were made in the diagnostic criteria of ADHD in the DSM-5: ADHD was 
moved from the disruptive behavior disorders category, which includes conduct disorder (CD) 
and oppositional defiant disorder (ODD), and reclassified under the NDD umbrella, together 
with intellectual disabilities (ID), communication disorders, autism spectrum disorder (ASD), 
and specific learning and motor disorders. Further, the age of onset changed from prior to age 
7 to age 12, and age-appropriate criteria for assessment in adults were included. These changes 
were the result of more than a decade of research demonstrating the high degree of persistence 
in ADHD across the lifespan, variability in the age of onset, and considerable phenotypic and 
genotypic overlap with other NDDs. 
2.1.1 Prevalence 
ADHD affects 5-7% of children19,20 and 2.5-5% of adults worldwide.21,22 Variability is 
primarily explained by methodological differences between studies, including diagnostic 
criteria used, source of information, and requirement of functional impairment for a 
diagnosis.21,23 Although there is concern regarding the rising rates of clinical ADHD 
diagnoses, there is no strong evidence to suggest that the prevalence of the underlying 
symptoms have increased over the past three decades according to meta-analyses.21 In a 
recent Swedish study, clinical diagnosis of ADHD were found to have increased fivefold 
from 2004 to 2014. However, the prevalence of diagnostic-level ADHD based on parent-
ratings among 19,271 9-year old twins were found to not changed significantly over time.24 
Research suggest that increased rates of clinically diagnosed ADHD may be largely 
explained by changes in clinical practices, greater public awareness of ADHD, and better 
access to healthcare. Nonetheless, over-diagnosis in certain age groups and geographical 
areas cannot be ruled out, whereas under-diagnosis is likely still an issue in females and adult 
populations, although this seem to be changing.25-29 In childhood, boys are significantly more 
likely have an ADHD diagnosis than girls, with a male-to-female sex ratio of 4:1 in clinical 
samples and 2.4:1 in population-based samples.30 These differences decrease with age.31 The 
reason for such sex difference remain largely unknown.32  
2.1.2 Pharmacological treatment  
Stimulant mediations are first-line pharmacological treatment for ADHD. Currently approved 
medications in Sweden are methylphenidate, amphetamine, dexamphetamine, and 
lisdexamfetamine. ADHD can also be treated with non-stimulant medications when patients 
do not respond to stimulant treatment, in the presence of comorbidities where there are 
concerns regarding the pharmaceutical action of stimulants, or when wishing to avoid their 
addictive potential. Non-stimulant medications approved in Sweden are atomoxtine, and since 
2015, guanfacin. Treatment guidelines from the Swedish Medical Products Agency 
recommend pharmacotherapy with methylphenidate from age six onward, when considered 
necessary and in conjunction with non-pharmacological interventions.33 
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There is considerable support for the short-term efficacy of stimulant medication treatment, 
and to a lesser extent non-stimulant medications, in the reduction of ADHD core symptoms in 
children and adults.34,35 Evidence from pharmacoepidemiological studies further suggest that 
pharmacological treatment of ADHD is associated with a decreased risk of crime,36 accidents 
and injuries,37,38 suicide,39,40 academic failure41, and development of later substance use and 
mood disorders.42,43 Common adverse effects of stimulants include small increases in blood 
pressure, headache, sleep disturbances, decreased appetite, abdominal pain, and small, 
although often not persistent, delays in growth amongst children.44 Whilst treatment is 
considered relatively safe in patients with ADHD alone, less is known about the safety in 
patients with comorbid conditions, including epilepsy (see section 2.3.2.6).35,44,45 
In the past two decades, prescription rates of ADHD medications have progressively increased, 
with the highest rates observed in western countries.46,47 In the Nordic countries, the highest 
increase of prevalent and incident users are reported in Sweden, Iceland and Finland (Figure 
2.1),48 with variations reported by geographic region within countries.33,49  In general, 
increasing prescription rates tend to follow the increased prevalence of ADHD diganoses.33,49  
Figure 2.1. Annual prevalence (per 1000 boys/girls) and annual incidence (new users per 1000 
boys/girls) of ADHD drug use among boys and girls aged 6–17 years by country, 2008–2012. 
       
Note: New users were defined as not filling a prescription for ADHD drugs during the previous 24 
months. ©2016 Nordic Association for the Publication of BCPT (former Nordic Pharmacological 
Society). From Furu K, et al. Basic & Clinical Pharmacology & Toxicology. Volume 120, Issue 4, 
pages 373-379, 30 JAN 2017 DOI: 10.1111/bcpt.12724. Reproduced with permission from Wiley Press.  
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2.1.3 Etiology  
It is well established that genetic factors strongly contribute to the disease liability in ADHD.50-
52 Whilst there are non-genetic and environmental factors that have been robustly associated 
with ADHD, the causal nature of such factors, and their interplay with genetic risk, remain 
unclear.1 Much of our current understanding of the etiology of ADHD comes from quantitative 
genetic research. Interestingly, evidence from more recent and fast-paced advances in 
molecular genetic ADHD research generally supports many of the robust, replicated findings 
from twin- and family studies. An overview of these findings is provided Table 2.2 and 
discussed throughout this thesis.  
2.1.3.1 Genetic factors in the etiology of ADHD 
Meta-analyses of twin studies have estimated the heritability (i.e. the proportion of variation in 
a trait that can be attributed to genetic factors) of ADHD to be 70-80% in childhood, making it 
one of the most heritable psychiatric conditions.50 Heritability estimates are similar across sex 
and symptom dimensions of inattention and hyperactivity/impulsivity.50,53-55 Although 
heritability estimates of ADHD in adults tend be lower, this appears to be largely explained by 
rater effects, with self-ratings which are commonly used in adult samples leading to lower 
heritability estimates. When estimated from multiple raters or clinical diagnoses, heritability 
estimates for ADHD do not differ substantially with age.51 Twin studies have reported strong 
genetic links between clinically relevant ADHD and subthreshold variation in ADHD,56,57 and 
a genetic correlation (rg) of 0.56 between ICD-based ADHD and ADHD symptoms.
58 This 
suggest that the clinical diagnosis of ADHD represents the extreme end of ADHD traits that 
are continuously distributed in the population, and that the genetic factors which influence the 
clinical disorder also account for the symptoms distribution in the population. 
More recent molecular genetic studies have provided convincing direct evidence that ADHD 
is a highly polygenic trait (i.e. many genes of small effect contributing to disorder liability). 
The largest genome-wide association study (GWAS) of ADHD to date, including 20,183 cases 
and 35,191 controls, has identified 12 genome-wide significant independent loci associated 
with ADHD case status.59 The study also showed that when estimating heritability from all 
common genetic variants (i.e. single nucleotide polymorphisms [SNPs]) measured in the 
GWAS, the SNP-based heritability of clinical ADHD was estimated at 22%.59 Similarly, 
previous estimates from GWAS data collected in population-based samples have reported 
SNP-based heritability of 5% to 34% for ADHD symptoms.60 Further, several recent studies 
suggest that rare mutations (e.g. copy number variants [CNVs] and non-inherited de novo 
mutations) are also implicated in the disease etiology of ADHD.1,61-63 Molecular genetic 
findings also support the dimensional nature of ADHD; when considered en masse, genetic 
risk variants associated with clinical ADHD have been found to predict variation in ADHD 
symptoms,58,64-67 and vice versa.68 Further, the genetic correlation between GWAS summary 
statics based on clinical ADHD and ADHD symptoms has been estimated at rg=0.94,
59,60 
suggesting a near complete genetic overlap across clinically defined ADHD and population 
variation in ADHD symptoms.  
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Table 2.2. Understanding the etiology of ADHD: A summary of the top replicated findings 
from quantitative and molecular genetic research 
Finding Quantitative genetic Molecular genetic 
ADHD shows substantial genetic 
influence by many genes of small 
effect 
 Twin-based h2 =70-
80%50,69 
 
 12 independent genome-
wide significant loci 
associated with ADHD 
case status59 
 
 SNP-based h2  = 22%59 
 
 Rare variants associated 
with ADHD52,61-63 
Clinical ADHD and ADHD 
symptoms in the population are 
underpinned by the same genetic 
factors  
 Strong genetic link 
between extreme and 
subthreshold variation in 
ADHD56 
 
 Twin rg = 0.56 between 
ICD-based ADHD and 
ADHD symptoms in the 
population58 
 rg=0.94 between clinical 
ADHD and ADHD 
symptoms59,60 
 
 PRS for clinical ADHD 
predicts ADHD 
symptoms58,64-67, and vice 
versa68 
Phenotypic correlations between 
ADHD and comorbid traits show 
substantial genetic mediation 
Twin rg with ADHD (range) 
 ASD (0.54-0.87) 9  
 LD (0.31-0.41) 70-72  
 ODD/CD (0.46-0.74) 73-76 
 Anxiety (0.45-0.58) 9 
 Depression (0.34-0.77) 9 
Significant rg or PRS 
association with ADHD 
 ASD64,77,78  
 IQ, educational attinment, 
and LD59,79-82  
 CD83  
 Depression59,81 
 
Stability in ADHD across ages is 
mainly due to genetics 
 h2 in ADHD is stable 
across lifespan51 
 
 Genetic factor contribute to 
stability across ages 
 ADHD PRS more strongly 
associated with persistent 
ADHD65 
Many ‘environmental’ risk factors for 
ADHD are genetically mediated 
 Association between 
smoking during pregnancy 
and offspring ADHD is 
genetically mediated84-86 
 ADHD is genetically 
associated with smoking  
(rg =0.48)59,81 
Most environmental effects 
influencing ADHD are not shared by 
within families 
 Limited evidence for role 
of twin and sibling shared 
environment in ADHD69,87 
na 
Note: h2, twin or SNP-based heritability. na, not available. PRS, polygenic risk score (see section 5.2 
3). rg, twin or SNP-based genetic correlation. Table adapted from Plomin., et al (2016).88 
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2.1.3.2 Non-genetic factors in ADHD 
Observational studies have linked ADHD to several non-genetic risk factors, including pre- 
and perinatal conditions, toxins, dietary factors, and psychosocial adversities.89 Yet, it remains 
unclear whether they represent causal risk factors. For example, smoking during pregnancy 
was long postulated to be a causal risk factor for offspring ADHD, but evidence from 
genetically informative studies strongly suggests that the association is better explained by 
unmeasured familial confounding.84,85,90 In contrast, risk factors such as low birth weight, 
advanced paternal age at childbearing, low family income, and severe psychosocial 
deprivation, continue to show associations with ADHD after accounting for important familial 
confounding, suggesting these may represent causal risk factors for ADHD.91-94 Emerging 
evidence suggests a potential role of pre- and perinatal exposure to environmental toxins95 and 
medication use96-99 in the risk of ADHD but more research is needed to make firm conclusions. 
2.2 DEVELOPMENT IN ADHD 
Although ADHD was long considered a childhood limited disorder, it is now generally 
recognized that ADHD can be a chronic disorder associated with impairment in psychosocial, 
educational, occupational, and health related outcomes across the lifespan.100-102 Meta-analyses 
of longitudinal studies suggest that whilst only about 15% of childhood cases retain a full 
diagnoses in early adulthood, an additional 65% continue to experience symptoms at an 
impairing level.4 It remains largely unknown why symptoms remit for some and persist in 
others, however genetic factors and maturation have been associated with differential 
developmental trajectories in ADHD.5,103 
2.2.1.1 Genetic factors and development in ADHD 
Quantitative genetic studies suggest that persistence and remittance in ADHD are to some 
extent underpinned by different genetic factors. Family studies have found evidence for higher 
familial risk in relatives of adult ADHD cases, suggesting that persistent ADHD may be 
associated with a higher genetic burden.69,104,105 Longitudinal twin studies have shown that 
stability in ADHD symptoms across ages is largely due to the stable genetic factors, whereas  
developmental changes in symptoms levels appear to be largely due to environmental factors 
and the emergence of new genetic factors influencing ADHD at later ages.7,53,54,57,106,107 At least 
one longitudinal molecular genetic study has found individuals with persistent ADHD 
trajectories to have a higher burden of common ADHD associated variants, as compared to 
individuals with childhood-limited ADHD.65 Together, evidence of stable genetic risk suggest 
that childhood ADHD and the adult form of the disorder are genetically linked, whereas 
evidence of dynamic genetic risk factors suggests that the set of genetic variants accounting for 
the onset of ADHD partly differs from those accounting for the persistence and remission of 
the disorder. 
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2.2.1.2 Maturation and ADHD 
Neuro-imaging data have shown that children with ADHD attain peak cortical thickness and 
surface area 2-3 years later than controls, suggesting that ADHD may be related to delayed 
brain maturation.108 Similar results have been found in normally developing children, where 
higher levels of attention and hyperactivity/impulsivity have been associated with slower 
cortical maturation.109,110 Interestingly, there is some evidence to suggest that remittance of 
ADHD symptoms may be associated with a maturational catch-up in cortical development, 
whereas persistence of symptoms seem to be associated with atypical developmental 
trajectories of fixed or accelerated cortical thinning.5Although such findings suggests that 
ADHD in childhood may be linked to late neurodevelopmental maturation, the role of 
maturation in ADHD requires further research.  
Several epidemiological studies have reported that birth-month is associated with the receiving 
a clinical ADHD diagnosis and medications, with a higher risk among children who are born 
late in the school-year and therefore the youngest in their grade. This effect has been found in 
countries with different school and health-care systems (i.e., Sweden, Norway, the US, Canada, 
Netherlands, Germany, Iceland, Spain, Israel, Australia and Taiwan).111-122 Although these 
findings may in part reflect later neurodevelopmental maturation among the youngest children 
in a school-year, it likely also reflects an increased risk of misdiagnosis of ADHD due to parents 
and teachers subjective comparisons of immaturity across children within a school-year.111   
Considering the age-dependent decline of ADHD symptoms, it is possible that perceived 
immaturity is more important for ADHD in childhood compared with adulthood, where 
maturational differences even out. Further, some of the dynamic genetic effects reported in 
developmental trajectories of ADHD could in part reflect etiological factor related to 
maturation. Therefore, longitudinal, genetic research is needed to understand the role of 
perceived immaturity in the development of ADHD, and how genetic and environmental 
influences contribute to the association across development. 
2.3 COMORBIDITY IN ADHD  
Comorbidity is the rule, rather than the exception in ADHD, with 60-70% of ADHD cases 
reported to have at least one or more comorbid psychiatric disorder.8,123 In childhood, which is 
the primary focus of this thesis, the most common co-occurring conditions are NDDs and 
externalizing problems, including CD and ODD. Prevalent comorbidities with a typically later 
onset extends to internalizing disorders, including depression and anxiety.8,124,125 Beyond 
psychiatric comorbidity, there is a growing awareness that ADHD is also associated with 
neurological conditions, including epilepsy,14,126 which is an additional focus of this thesis 
work. Despite the high level of comorbidity between ADHD and psychiatric disorders, and to 
a lesser extent neurological conditions, the genetic and environmental causes underpinning 
these associations are not fully understood.  
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2.3.1 ADHD and related childhood psychopathology 
2.3.1.1 Shared genetic risk between ADHD and related childhood psychopathology 
Quantitative genetic studies provide strong evidence that phenotypic correlations between 
ADHD and comorbid conditions are mediated by shared genetic factors (Table 2.2). Several 
twin studies have reported a substantial overlap between ADHD and ASD, measured as both 
as traits and categorical disorders.9 Register-based family studies have also reported a 
significantly increased risk of ADHD in relatives of individuals with ASD.127 Genetic 
associations between ADHD and learning problems have also been reported, with difficulties 
in reading and mathematics showing a stronger genetic association with inattentive, rather than 
hyperactive/impulsive, symptoms.70-72 One recent large-scale family study found significant 
familial co-aggregation for ADHD and ID, and evidence suggesting that 91% of the cross-
disorder correlation could be attributed genetic factors.128 A large number of twin and family 
studies have demonstrated genetic overlaps of ADHD with ODD and CD, and comorbidity 
across all three conditions seems largely influenced by one shared genetic factor.73-75,129 
Although less researched, family studies suggest that the co-occurrence of ADHD, depression 
and anxiety is influenced by shared familial factors.130-132, and twin studies have reported 
moderate to strong genetic correlations between the conditions.9,133  
Recent evidence from molecular genetic studies have generally confirmed cross-disorder 
genetic associations previously found quantitative genetic studies. Genetic risk implicated in 
ADHD have been associated with lower cognitive abilities, IQ, and poorer educational 
attainment.59,79-81 Several studies have reported significant genetic overlap between ADHD and 
ASD, at the level of both common and rare variants,61,64,77,78 whereas other studies found no 
association.134-137 Higher ADHD genetic burden has also been reported in children diagnosed 
with ADHD and comorbid CD, relative to children with ADHD-only and controls.83 Three 
studies have reported no significant genetic overlap between ADHD, anxiety and 
depression,136-138 whereas two more recent studies, relying on ADHD GWAS data with larger 
sample size, have identified a significant genetic association with depression.59,81 
2.3.1.2 A shared genetic liability across all childhood psychopathology? 
Based on the extensive phenotypic and genotypic overlap observed in psychiatry, is has been 
hypothesized that psychiatric comorbidity may be attributed to a general genetic liability that 
increases the risk for virtually all psychiatric conditions.139,140 In twin studies, a latent genetic 
factor has been found to account for up to 45% of co-variance across childhood externalizing, 
internalizing and phobia symptoms,139 and 31% of co-variance across childhood 
neurodevelopmental symptoms.141 Similar results have been reported for register-based clinical 
diagnoses, with a general genetic factor explaining 10-36% of disorder liability across several 
psychiatric diagnoses.142 The twin-based heritability of such a general psychopathology factor 
has been estimated at 43% in one twin-study,143  and the SNP-based heritability at 18%144 and 
38%145 in two pediatric population samples. Assessing the extent to which cross-disorder 
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associations in psychiatry can be attributed to a broadly shared genetic liability may provide 
insight into the genetic architecture of childhood psychopathology.  
2.3.2 ADHD and epilepsy  
Compared to the available evidence on comorbidity in ADHD and related psychiatric 
conditions, the association between ADHD and epilepsy has received relatively little research 
attention. However, population-based studies have shown that children with epilepsy have a 3-
to-5-fold increased risk of clinical ADHD,14,126,146 with a similar to the risk increase for epilepsy 
reported in children with ADHD.147 Despite the strong association, the underlying mechanisms 
influencing comorbid ADHD and epilepsy are not well understood. Further, epilepsy is also 
associated with an elevated risk for a range of other NDDs, leading to the hypothesis that 
epilepsy may share genetic risk factors with the broader neurodevelopment continuum.148 
2.3.2.1 Epilepsy 
Epilepsy is the most common neurological condition in children. Descriptions of epilepsy date 
back to antiquity, with written records found as early as 4000 BC.149 The current operational 
definition of epilepsy by the International League Against Epilepsy (ILAE)150 is  
 At least 2 unprovoked (or reflex) seizures occurring greater than 24 hours apart.  
 One unprovoked (or reflex) seizure and a probability of further seizures similar to the 
general recurrence risk (at least 60%) after 2 unprovoked seizures, occurring over the next 
10 years.  
  Diagnosis of an epilepsy syndrome 
o Epilepsy is considered to be resolved for individuals who had an age-dependent 
epilepsy syndrome but are now past the applicable age or those who have remained 
seizure-free for the last 10 years, with no seizure medicines for the last 5 years. 
Figure 2.2 Classification of seizure types (basic version) from ILAE, 2017 
Source: https://www.epilepsy.com/learn/types-seizures 
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Seizures are in turn defined as “a transient occurrence of signs and/or symptoms due to 
abnormal excessive or synchronous neuronal activity in the brain”, and categorized as focal 
(originating in one brain half) or generalized (involving both brain halves)(Figure 2.2).151,152 
Epilepsy diagnoses are made based on clinical assessment of both seizure and epilepsy type, 
and commonly coded according to ICD-codes. As the classification of epilepsies are subject to 
continuous revision, correspondence between ILEA classification and the ICD is not complete, 
nor is mapping across ICD versions.153 For these reasons, there is limited discriminative 
validity for studying epilepsy types using register data.154  
2.3.2.2 Prevalence and incidence of epilepsy 
Epilepsy affects approximately 1% of children at any given time-point13, however prevalence 
and incidence rates vary considerably around the world and with age. Age-adjusted incidence 
range from 16 to 51 per 100,000 worldwide (with some exceptions),155 whereas incident rates 
in children range from 35 to 128 per 100,000.156 Variation across estimates is partly due 
methodological differences across studies, but factors such as access to health care, regional 
environmental exposures, ethnicity, and socioeconomic status are also likely to play a role. 
Unlike ADHD, the prevalence of epilepsy does not differ significantly across gender.155,157 
2.3.2.3 Etiology of epilepsy 
Epilepsy encompasses a collection of heterogeneous seizure disorders, with diverse clinical 
characteristics that preclude a singular etiological mechanism. Known risk factors for epilepsy 
include infections, certain metabolic and autoimmune disorders, head injuries, strokes, and 
tumours. Nevertheless, the cause of epilepsy is unknown for approximately half of all cases. A 
genetic etiology has been implicated in many types of epilepsies, yet, with the exception of 
certain monogenic epilepsy syndromes, there risk genes implicated are generally unknown.152 
Family studies suggest that first-degree relatives of epilepsy cases have a 2-6 fold increased 
risk of epilepsy themselves, depending on epilepsy type.158 Similarly, twin studies suggest that 
genetic factors play a role in the etiology of epilepsy. 159 Molecular genetic research has 
identified several de novo mutations and CNVs contributing to both severe and mild 
epilepsies.160 In the largest GWAS of epilepsy to date, including 8696 cases and 26,157 
controls, one genome-wide hit was identified for generalized epilepsy and none for focal 
epilepsy.161 
2.3.2.4 Underlying causes of comorbid ADHD and epilepsy 
Several mechanisms have been proposed to influence comorbidity between ADHD and 
epilepsy, including adverse effects of antiepileptic medications (AEDs) and recurrent seizures 
leading to ADHD symptoms in epilepsy. Nevertheless, at least two studies have shown that 
ADHD symptoms are often present prior to first epileptic seizure and in medication naïve 
epilepsy patients. Together, this suggests that epilepsy and ADHD can be associated 
independently of the effect of seizures and AEDs.162,163 Another postulated explanation is that 
epilepsy and ADHD share genetic risk factors.  
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2.3.2.5 Shared genetic risk in ADHD and epilepsy 
Family studies provide some evidence for familial co-aggregation between the ADHD and 
epilipsy.164,165 Results from a large Norwegian study reported a higher risk of ADHD in 
offspring of mothers with epilepsy, compared to the general population (relative risk 1.7, 
95%CI 1.1–2.7).165 However, studies involving only mother-offspring pairs cannot disentangle 
familial transmission from pregnancy related risk factors.158 There are, to our knowledge, no 
twin studies investigating the association between ADHD and epilepsy. In terms of molecular 
genetic evidence, rare inherited CNVs have been implicated in many NDDs, including ASD, 
ID, ADHD and epilepsy, with some evidence for deletions and duplications in overlapping 
genomic regions.148,166 At the level of common variants, molecular studies have not found any 
significant genetic correlation between ADHD and epilepsy. Nevertheless, this may be related 
to the relatively low sample sizes, particularly of the epilepsy GWAS sample.135 Large-scale, 
well-powered family-based studies, including multiple types of relatives, can address several 
limitations of the research to date and improve current understanding of the causes underlying 
comorbidity between ADHD and epilepsy. 
2.3.2.6 Pharmacological treatment safety of ADHD in epilepsy 
There are longstanding concerns that ADHD pharmacological treatment, especially stimulant 
formulations, may lower the seizure threshold, interfere with seizure control and in rare cases, 
even induce new onset seizures in previously seizure free patients.167 North American and 
European regulatory agencies caution against the use of ADHD medications in the presence of 
active seizures or a history of seizures.33,168 However, the empirical evidence for an increased 
risk of seizures related to ADHD medication treatment is sparse. Many previous studies are 
limited by small sample sizes, exclusion of patients with active seizures, and insufficient 
consideration of important confounding factors, such as individual variation in baseline 
disorder severity. An overview of the current research is presented in Table 2.3.  
To summarize, stimulants do not appear to increase the frequency of seizures in well-controlled 
epilepsy.169-173 Other studies have reported either inconclusive results due to limited sample 
size or potential evidence of seizure exacerbation in patients with active epilepsy.174-176 Two 
studies found methylphenidates safe in difficult-to-treat epilepsies,177 and in patients with brain 
injury and active seizures.178 Although less researched, there is no strong support for an 
increased risk of seizures associated with atomoxetine. Finally, two studies have reported a 
decreased risk of seizures associated with ADHD medications. One of these is a recent large-
scale, medical-claims study that relied on a within-individual design to adjust for confounding 
factors that may differ between individuals and influence the association between ADHD 
medication and seizures.179 Although these findings do not support the hypothesis of an 
increased risk of seizures related to ADHD medication, findings need to be replicated in other 
populations, using complimentary analytic methods. Further, there is still a dearth of 
knowledge regarding the safety of ADHD treatment in patients with epilepsy and additional 
NDD comorbidities, where polypharmacy and severity of neurodevelopmental insults may be 
of greater concern.  
  13 
Table 2.3. Overview of studies assessing ADHD medication and seizure risk 
PUBLICATION  POPULATION  EFFECT DRUG N  STUDY TYPE 
Feldman et al., 
1989 
Well-controlled 
epilepsy and 
ADHD 
No risk 
increase 
Stimulant 10 Double-blind 
medication-placebo 
crossover study * 
Wroblewski et 
al., 1992 
Seizures due to 
brain injury 
Risk reduction Stimulant 30 Retrospective 
observational study 
Gross-Tsur et al.,  
1997 
Active or well-
controlled 
epilepsy and 
ADHD 
Increased risk 
in participants 
with active 
epilepsy 
Stimulant 30 4 months open-trial 
Hemmer et al., 
2001 
ADHD only Increased risk 
in participants 
with EEG 
abnormalities 
Stimulant 234 Observational 
retrospective 
study* 
Gucuyener et al., 
2003 
Active epilepsy 
or EEG 
abnormalities 
and ADHD 
No risk 
increase 
Stimulant 119 1 year open-trial 
Van der Feltz-
Cornelis et al., 
2006 
Active epilepsy 
and adult 
ADHD  
No risk 
increase 
Stimulant 6 6 weeks open-trial 
Gonzalez-
Heydrich et al., 
2010 
Active epilepsy 
and ADHD 
Increased risk  Stimulant 33 2-6 weeks double-
blind placebo-
controlled 
crossover trial 
Santos et al., 
2013 
Complex 
epilepsy 
Reduced risk Stimulant 22 3 month open 
label, non-
controlled trial 
Rheims et al., 
2016 
Active or well-
controlled 
epilepsy and 
ADHD 
No risk 
increase 
Stimulant 167 Prospective 
observational study 
with 12-16 weeks 
follow-up 
Adams et al., 
2017 
Adult EP No risk 
increase 
Stimulant 31 Double-blind, 
randomized, 
single-dose trial 
Wiggs et al., 
2017 
ADHD with and 
without epilepsy 
Reduced risk Stimulant & 
Atomoxetine 
  
 
801,838  
Medical-claims 
database study 
Wernicke et al., 
2007 
ADHD-EP No risk 
increase 
Atomoxetine na Review of clinical 
data in medical 
trial databases 
McAfee et al., 
2008 
ADHD only No risk 
increase 
Atomoxetine 34,727 Medical-claims 
database study 
Torres et al., 
2011 
Active epilepsy  No risk 
increase 
Atomoxetine 27 Medical chart 
review 
Note: Majority of reported effects were not significant, due to limited power. * indicates insufficient 
study information to report follow-up time or exact study designs. 
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3 AIMS  
3.1 OVERARCHING AIM 
The overarching aim of this thesis was two-fold: 1) to explore the role of shared genetic liability 
for maturity and comorbidity in ADHD, in order to increase the understanding of the genetic 
architecture of prevalent childhood psychopathology. 2) To investigate the underlying causes 
of comorbid ADHD and epilepsy, and to evaluate treatment safety in this patient group.  
3.2 SPECIFIC AIMS  
Study 1. To examine whether perceived immaturity in childhood is associated with 
ADHD symptoms across development from childhood to early adulthood, and to estimate the 
contribution of genetic and environmental factors to the association. 
Study 2. To examine whether ADHD genetic risk is associated with a range of 
neurodevelopmental, externalizing, and internalizing childhood psychiatric traits, and to 
investigate the extent to which such associations can be attributed to a general liability 
towards broad childhood psychopathology. 
Study 3. To investigate the familial co-aggregation of ADHD and epilepsy, and to 
estimate the contribution of genetic and environmental risk factors to their co-occurrence. 
Study 4. To examine whether incident and repeated ADHD medication treatment is 
associated with an increased risk of seizures in individuals with a seizure history, with and 
without additional NDDs. 
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4 DATA SOURCES AND MEASURES 
Study 1 and 2 of this thesis takes advantage of data from two prospective cohort studies nested 
within the Swedish Twin Register (STR). STR was established in the 1960s, and now includes 
almost 200,000 twins, of which zygosity information is available for nearly 85 000 twin pairs. 
STR is the largest twin register in the world, and contains rich health related and 
sociodemographic data across the life span. The STR is hosted at the Department of Medical 
Epidemiology and Biostatistics at Karolinska Institutet.  
4.1 THE SWEDISH TWIN STUDY OF CHILD AND ADOLESCENT 
DEVELOPMENT (TCHAD) 
TCHAD is a prospective, longitudinal twin study targeting all 1,480 twin pairs born in Sweden 
from May 1985 to December 1986, who were alive and living in Sweden in 1994.180 Twins 
and their parents were contacted by mailed questionnaires when the twins were aged 8-9, 13-
14, 16-17, and 19-20 years. Majority of parent reported information was provided by mothers 
rather than fathers (range: 75%–90%). Data was collected across broad socio-demographic and 
health related domains.180  Zygosity was assessed via DNA when available or determined based 
on an algorithm derived for validated zygosity questionnaires. In case of contradictions 
between the assignments (n=100), zygosity was set to unknown106 and twins were excluded 
from analyses. Parent-ratings were collected at all four ages, with a response rate of 75%, 73%, 
74%, 78%, and twin self-ratings at ages 13-14, 16-17, and 19-20 years with a response rate of 
78%, 82%, 59%. The sample has been shown to be representative in terms of neighborhood 
characteristics for educational level, unemployment, and crime-rates. However, families from 
more ethnically diverse areas were less likely to participate.181 Attrition rate analyses have 
reported no significant differences in sex and parent-rated ADHD symptoms between 
responders and subjects lost to follow-up at wave 2. Between wave 2 and 3, attrition analyses 
showed no statistically significant difference for sex, family socioeconomic status and parent-
rated inattention between responders and non-responders. However non-responders in wave 3 
did have significantly higher rates of hyperactivity/impulsivity symptoms.181Similary, non-
responders at wave 4 were more likely to be male and have higher levels of childhood ADHD 
symptoms.106 
4.1.1 Measures in TCHAD 
4.1.1.1 ADHD  
Study 1 was conducted using data from TCHAD, relying parent and self-rating of ADHD 
symptoms assessed using The Achenbach System of Empirically Based Assessment (ASEBA). 
ASEBA scales are empirically derived, standardized questionnaires consisting of similar, but 
developmentally appropriate items for parent and self-ratings of problems experienced in the 
last six months. All items were rated on a 3-point Likert scale (1=not true, 2=sometimes true, 
3=often true) and summed, with higher scores reflecting greater problems. Parent-ratings were 
collected using the Child Behavior Checklist (CBCL)182 at ages 8 to 17 years, and the Adult 
Behavior Checklist (ABCL)183 at ages 19 to 20 years. Self-ratings were collected using the 
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Youth Self-Report form (YSR)184 at ages 13 to 17 years and the Adult Self-Report form 
(ASR)183 at ages 19 to 20 years. ADHD was assessed using the Attention Problem (AP) scale, 
which including both inattention and hyperactivity symptoms. The psychometric properties of 
the AP scales have been evaluated in population-based and clinical samples, with results 
showing good reliability and convergent and discriminant validity 185,186  
4.1.1.2 Relative Immaturity 
Perceived level of maturation, from now referred to as relative immaturity (RI), was assessed 
in TCHAD using parent-ratings on two items assessed when the twins were aged 8-9 years. 
For item one, parents were asked to estimate their child’s level of maturity in relation to same 
age peers on a 5-point scale (1=very mature, 2=somewhat mature, 3=average, 4=somewhat 
immature, 5=very immature).  For item two, parents were asked to estimate their child’s 
perceived age independent of their chronologic age. The correlation between the two items was 
r=0.75 and the items were standardized and summed to create a continuous measure, with 
higher scores indicating higher level of immaturity. The RI measure has been evaluated in two 
prior studies. Within the TCHAD sample, RI was showed weak correlations to measures of 
early physical maturation (birth weight, r=0.19; age at walking, r=0.10; age at teething, r=0.06) 
and weak to moderate correlations with indicators of early mental maturation (ability to handle 
scissors, r=0.38; ability to tell the time from a watch, r=0.24).187 In a separate case-control 
study, higher RI was related to a more childish body appearance, fine motor function problems, 
peer problems, lower general knowledge and slightly lower mean IQ scores.188 in Study 1, RI 
was also significantly associated with birth-month, with younger children within each school-
year showing higher RI. 
4.2 THE CHILD AND ADOLESCENT TWIN STUDY IN SWEDEN (CATSS) 
CATSS is an ongoing nationwide study targeting all twins born in Sweden since the 1st of July 
1992 189. The study was initiated in 2004, and since then parents of twins identified via the STR 
are systematically invited to participate in a telephone interview regarding their children’s 
health and social environment on the twins 9th birthday. In the first three years of the study, 12 
year old twins were also included. By January 2017, parental interviews have been completed 
for more than 30,000 twins, with an overall response rate of ~70%. DNA has been collected 
for more than 12,500 of the participants, and further genotyping is underway.190  Analyses of 
the differences between non-responders and responders, based on a merge of data with national 
registers, suggest that non-responders on average have lower socio-economic and more 
neuropsychiatric diagnoses, including ADHD and ASD.189   
4.2.1 Measures in CATSS 
4.2.1.1 The Autism-Tics AD/HD and other Comorbidities inventory (A-TAC) 
Study 2 was conducted using data from the CATSS-9/12 cohort, were primary assessment is 
conducted using A-TAC.189 A-TAC is a comprehensive parental telephone interview, 
administered by laypersons, and designed for use in large-scale epidemiological settings.191 
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Items in A-TAC are formulated to reflect symptom criteria for child psychiatric disorder 
according to the DSM-IV. Questions are asked in a lifetime perspective, in relation to same-
age peers and coded according to three response categories (no=0, yes to some extent=1, 
yes=2). A-TAC consists of 96 symptom items that have been assessed in all waves of CATSS. 
Several validation studies have been conducted for A-TAC, showing excellent inter-rater 
agreements (<0.90) and good to excellent test re-test reliability (<0.70). Diagnostic cut-offs  for 
ADHD and ASD have been found to show excellent sensitivity and specificity, with cut-offs 
for other diagnosis’s, including learning disorders (LD), ODD and CD, showing moderate to 
good classifications.191-194 In the first five waves of CATSS-9/12, eight anxiety and five 
depression items were also included in the A-TAC interview. The internal and external validity 
of these items scales have not been formally assessed. In subsequent data collection, A-TAC 
internalizing items were replaced with two more in-depth, validated anxiety and depression 
questionnaires. 
4.2.1.2 Screen for Child Anxiety Related Emotional Disorders (SCARED) 
SCARED is a 41 item questionnaire measuring child and adolescent anxiety symptoms 
experienced in the last three months, coded according to three response categories (no=0, yes 
to some extent=1, yes=2).195,196 The questionnaire measures symptoms of five anxiety 
subtypes; panic disorder (PD), generalized anxiety disorder (GAD), separation anxiety disorder 
(SAD), school anxiety (SA) and social phobia (SP). Validity and psychometric properties of 
SCARED have been validate in different cultures and ages, showing strong internal 
consistency, a five-factor structure corresponding to the diagnostic subscales, and moderate 
predictive validity for clinical diagnoses of anxiety.195-199  
4.2.1.3 Short Mood and Feelings Questionnaire (SMFQ). 
SMFQ is a 13 item questionnaire measuring child and adolescent depressive symptoms 
experienced in the last two weeks, coded according to three response categories (no=0, yes to 
some extent=1, yes=2). 200,201 SMFQ has been validated, with strong internal consistency and 
moderate predictive validity for clinical diagnoses of depression.200-202.  
In study 2 of this thesis, parent-ratings of childhood psychopathology symptoms were used. 
The sample was split by available assessment for internalizing items. A-TAC assessment of 
anxiety and depression was used for twins born 1992-1997 (from now on referred to as the A-
TAC subsample), and SCARED and SMFQ for twins born from 1998 and onward (from now 
on referred to as the SMFQ/SCARED subsample). In addition to internalizing items, 49 
symptom items assessing ADHD, ASD, LD, ODD and CD were included. ADHD was further 
divided into the A-TAC subscales for attention and hyperactivity/impulsivity symptoms.  
4.2.1.4 Genotype data 
Collection of saliva samples for DNA extraction started in CATSS in 2008, in connection with 
being contacted for the telephone interview. Twins born earlier were re-contacted and asked to 
submit saliva samples. To date, a total of 11,551 individuals in CATSS have been genotyped 
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using the Illumina Infinium PsychArray-24 BeadChip. All genotype data were subjected to 
stringent quality control (QC) procedures applied to genotyped markers and individuals,67 
using standardized procedures (see Table S1 in manuscript for Study 2). Ancestry outliers were 
identified using principal components analysis and removed. After OQ, 561,187 genotyped 
SNPs and 11,081 samples were retained and genotypes for another 2,495 MZ twins were 
imputed from their genotyped co-twin. Genotype imputation was performed using Minimac3 
for 13,576 samples on autosomes with 1000-Genomes data (Phase 3, Version.5) as the 
reference panel. Only SNPs with good imputation quality (imputation R2 ≥ 0.8, MAF≥0.01) 
were retained. Genotype data was used to derive ADHD polygenic risk scores in Study 2. 
4.3 SWEDISH NATIONAL REGISTERS   
Study 3 and 4 of this thesis take advantage of Swedish nationwide registers. Data in these 
register are not primarily collected for research, but can be requested for such purposes from 
the register holders. National registers containing primarily demographic information are kept 
by Statistic Sweden, and the population-based national health registers by the National Board 
of Health and Welfare (NBHW). Since 1947, every resident in Sweden is assigned a ten-digit 
personal identity number (PIN). The PIN serves as a unique identifier for public administration 
registers in Sweden, thus enabling unambiguous linkage across national registers. Children 
born in Sweden are assigned a PIN number at birth, whereas immigrants who become 
permanent residents, or live in Sweden longer than one year, are assigned a PIN upon 
registration. The National Tax Board is responsible for administration of PIN numbers.203 
Total population register  
The Total Population Register (TPR) was established by Statistics Sweden in 1968. 
Information on births, deaths, place of residence, civil status, migration, relations and 
citizenship are reported from the local tax offices to the National Tax Board.204 Information 
from the TPR was used to obtain demographic data, including information on emigration, date 
of birth, and sex in Study 3 and 4. 
Multi-Generation Register  
The Multi-Generation Register (MGR) is part of the TPR and links all Swedish residents to 
their parents, allowing for identification of family pedigrees.205 The register was established in 
the early 1990s’ and includes all individuals, so-called index persons, born after 1932 and alive 
and registered in Sweden since January 1, 1961. Linkage between index persons and parents is 
feasible for parents who were alive and living in Sweden from 1947 onwards. Immigrated index 
persons are only linked to their parents if they immigrated together with parents before age 18.  
Information on family relatedness was used in study 3 to identify pairs of parent-offspring, full-
siblings, half-siblings and full cousins (see Figure 4.1 for example). 
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Figure 4.1. Graphic presentation of four generations in the Multi-Generation Register, where circles 
represents females and squares represents males. Different family constellations that can be identified 
from the register are suggested. Reproduced with permission from Anne Örtqvist. 
The Medical Birth Register  
The Medical Birth Register (MBR) is kept by the National Board of Health and Welfare 
(NBHW). The register contains information on prenatal and perinatal variables related to nearly 
all pregnancies and births in Sweden since 1973, with complete missing data for approximately 
2% of all births.206,207 Information in the register is obtained from medical records from the 
antenatal care of the mother, the delivery record and the record of the newborn infant 
examination. The MBR was used to identify the study population in Study 3. 
National Patient Register 
 The National Patient Register (NPR) was established in 1964 by the NBHW and covers 
somatic inpatient care since 1964 and psychiatric inpatient care since 1973, with complete 
coverage achieved from 1987. Data on outpatient visits to specialist physicians in public care 
are available since 2001, with approximately 80% coverage.208,209 The register includes 
information on dates of admission and discharge, whether the hospital visit was scheduled or 
not, the type of care unit, and the cause of hospitalization. Each discharge has one primary and 
up to seven secondary discharge diagnoses, coded according to the current version of the ICD.18 
Data from primary health care clinics are not included in the NPR. Information from the register 
was used to identify individuals with ADHD and epilepsy diagnoses in Study 3 and 4, as well 
as outcome seizure events and covariates in Study 4. 
The Prescribed Drug Register 
The Prescribed Drug Register (PDR) covers all dispensed prescriptions medications from 
outpatient and primary health care for all Swedish residents since July 1, 2005.210 The register 
contains information on the dispensed medication, including dosage, expenditure and 
reimbursement, age, sex and place of residence of the patient, prescription and dispensing date, 
a prescriber code and the prescriber’s profession. All drugs are classified according to the 
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international Anatomical Therapeutic Chemical (ATC) classification system. The PDR does 
not include information on medications sold over-the-counter, medications used in hospitals or 
prescribed medications that were not dispensed. The PDR was used to identify individuals who 
had received ADHD medications as a proxy for ADHD case status in Study 3, and to define 
ADHD medication periods as a time-varying exposure in Study 4. 
The Cause of Death Register  
The Cause of Death Register (CDR) was established in 1952, with complete coverage since 
1961. The CDR is updated yearly, and provides information on all deaths among Swedish 
residents, including both Swedish citizens and non-citizens. The register includes information 
on contributing causes of death, coded according to the ICD, and the date of death.204 The CDR 
was used to obtain date of death for censoring in Study 3 and 4. 
4.3.1 Measures in Swedish National Registers   
4.3.1.1 ADHD 
ADHD cases were defined via in- or outpatient discharge diagnosis of HKD according to ICD-
codes (ICD-9 314; ICD-10 F90) in the NPR. Further cases were identified via dispensations of 
ADHD medication in the PDR. Approved medications for treatment of ADHD in Sweden 
during the study period were methylphenidate [N06BA04], amphetamine [N06BA01], 
dexamfetamine [N06BA02], lisdexamfetamine [N06BA12], and atomoxetine [N06BA09]. We 
only considered diagnosis and medication dispensations after age three, as diagnosis prior to 
this age is unusual, and because medication treatment is not recommended for children under 
the age of six. In Study 4, ADHD cases were identified from the NPR only. ADHD case status 
was treated as categorical (0/1) life-time diagnosis in both Study 3 and 4. 
4.3.1.2 Epilepsy 
Epilepsy cases were defined via in- or outpatient discharge diagnosis for any type of epilepsy 
according to ICD-codes (ICD-8 345; ICD-9 345; ICD-10 G40, G41) in NPR. Epilepsy case 
status was treated as categorical (0/1) life-time diagnosis. In Study 3, earlier ICD revisions were 
used to identify epilepsy in the parent generation (ICD-7 353; ICD-8 345). In Study 4, ICD-8, 
9 and 10 were used to identify a cohort with a history of seizures. Additionally, inclusion 
criteria required that the first observable diagnosis in the NPR had occurred prior to age 30.  
Date of first identifiable seizure was used to define the start of follow-up, if the seizure occurred 
after age five or after 1st January 2006.  
4.3.1.3 Seizure events 
In Study 4, seizure events were the outcome of interest. Seizure events were defined as an 
unplanned in- or outpatient visit to hospital or specialist care with a primary discharge diagnosis 
for seizure according to ICD-10. For sensitivity analyses, we used a stricter seizure event 
definition, including only unplanned emergency care visits, ambulance rides or inpatient care 
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visits requiring overnight stay with a primary seizure discharge diagnosis. Discharge diagnosis 
for status epilepticus (G41), which by definition is an acute seizures, were also included. 
4.3.1.4 ADHD medication periods 
In Study 4, ADHD medication periods were treated as a time-varying exposure. All 
dispensations of ADHD medications (see ATC codes in section 4.3.1.1) in the PDR from 1 
January, 2006 until 31 December, 2013 were identified. For each individual with at least one 
record of prescribed ADHD medication, the follow-up time was divided into on- and off-
treatment periods (Figure 4.2).  
 
Figure 4.2. ADHD medication periods as a time-varying exposure, illustrated for 1 individual 
On-treatment periods were defined as a time period of at least two ADHD medication 
dispensations occurring no longer than six months (183 days) apart. Time periods not occupied 
by the on-treatment periods were defined as off-treatment. Each treatment period started on the 
date of the first prescription and ended on the date of the last prescription. We took 
dispensations in 2005 and 2014 into account when defining the treatment status over the first 
and the last periods during the follow-up (Figure 4.2). For sensitivity analyses, we varied the 
exposure definition by I) adding 90 days to the date of last prescription in each medication 
period, and II)  defining treatment periods as two subsequent prescriptions within 90 days, 
rather than 183 days. The 90 day cut-off was chosen as three months is the maximum quantity 
of drugs allowed at a single dispensation according to Swedish reimbursement regulations.211 
4.3.1.5 Covariates 
In Study 4, AED periods were defined based on dispensations for any drug belonging to 
ATC class N03A (antiepileptic drugs) in the PDR. AED periods were treated as a time-varying 
covariate, and defined the same as for ADHD medication (section 4.3.1.4). Life-time diagnosis 
for ASD (ICD-9 299; ICD-10 F84), ID (ICD-9 317-319; ICD-10 F70-F79), and other pervasive 
and specific developmental disorders (ICD-9 315; ICD-10 F80-F89) were obtained based on a 
discharge diagnosis in the NPR. These were used to stratify analyses based on the presence or 
absence of one or more additional NDDs, over and above epilepsy and ADHD.  
  
  23 
5 METHODS 
5.1 OVERVIEW OF STUDY METHODS AND MATERIALS 
 
STUDY PARTICIPANTS MEASURES STATISTICAL ANALYSES 
1 1,302 twin pairs 
from TCHAD 
born 1985 to 1986 
Exposure: Parent-rated immaturity 
relative to same age peers at ages 
8-9 years. 
 
Outcome: Parent- and self-rated 
ADHD symptoms assessed via 
ASEBA scales at ages 8-9, 13-14, 
16-17 and 19-20 years. 
 Longitudinal, multivariate, 
multi-rater twin model, 
estimated using structural 
equation modeling. 
 
2 13,457 twins aged 
9 or 12 from 
CATSS 
Exposure: ADHD polygenic risk 
scores  
 
Outcome: Parent-rated 
neurodevelopmental, externalizing 
and internalizing symptoms, 
assessed via A-TAC, SCARED 
and SMFQ 
 
 Covariates: Sex, age and six 
ancestry principal components  
 Confirmatory factor analysis 
and linear regressions, 
estimated using structural 
equation modeling.  
 
 Cluster robust standard error to 
account for non-independance 
of data. 
3 Relatives pairs  
identified from  
1,899,654 
individuals born 
in Sweden 1987-
2006  
Exposure: Epilepsy status in 
exposing relative 
 
Outcome: ADHD status in 
outcome relative* 
 
Covariates: Birth year and sex 
 Logistic regression to estimate 
familial aggregation. 
 
 Bivariate extended sibling 
model to estimate genetic and 
environmental effects, 
estimated using structural 
equation modeling. 
 
 Cluster robust standard error to 
account for non-independance 
data. 
4 44,827 individuals 
born 1968-2007, 
with a history of 
seizures  
Time-varying exposure: ADHD 
medication treatment  
 
Outcome: Time to seizure event 
 
Covariates: Time-varying AED 
medication treatment, age, sex and 
additional NDDs  
 Conditional Poission regression 
for incident ADHD medication 
analysis 
 
 (Stratified) Cox proportional 
hazard regression for repetead 
ADHD medication analysis 
Note: Study 1 and 3 are quantitative genetic studies, which do not aim to establish an exposure-outcome 
relationship, but rather to estimate the bi-directional association between the traits of interest and the relative 
importance of genetic and environmental factor for that associations. The terminology exposure and outcome is 
merely used for consistency. 
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5.2 STUDY DESIGNS   
All four studies included in this thesis are, at their core, variants of the classical observational 
study design, with the distinct feature that they by design also incorporate genetic information. 
Study 1, 3 and 4 rely on known family relationship, whereas Study 2 relies on directly measured 
genetic variants. The common purpose of all study designs included in this thesis, which can 
be described as genetically informative designs, is to quantify the importance of genetic and 
environmental factors in disorder associations, or to control for the influence of genetic 
confounding in exposure-outcome associations.  
5.2.1 Quantitative genetic designs 
Quantitative genetic designs include a range of study designs that are primarily concerned 
with answering the questions; 
I) To what extent does genetic factors contribute to the etiology of complex traits 
(i.e., traits that do now show a classical Mendelian inheritance)? 
II) What is the relative contribution of genetic and environmental factors to variance 
in complex traits? 
These question are addressed by studying the patterns of trait similarity across different types 
of relatives, who vary in their degree of genetic and environmental sharing. 212 
5.2.1.1 Family studies 
Family studies are concerned with investigating the degree of familial aggregation, or 
clustering, of a disorder or co-aggregation across disorders.212 Such clustering can be due 
genetic or environmental factors that are shared within the family. In family studies, the risk of 
a disorder in individuals of a relative with the same disorder is compared to the risk among 
individuals without a relative with the disorder. Similarly, familial co-aggregation estimates 
the risk of disorder A in individuals with a relative affected by disorder B, compared to the risk 
of disorder A among individuals who do not have a relative affected by disorder B. Having one 
(or several) relative(s) affected by a disorder can be considered a proxy of an individual’s 
genetic liability for the disorder in question. As this liability is fixed at conception, the exact 
timing of diagnosis carries little information and the association may be estimated using life-
time prevalence of disorder status for both the outcome person and relative. This is a reasonable 
estimation method of familial risk if the study population has passed through the period of 
risk,212 but not if many individuals in the cohort may still go on to develop the disorder (i.e. the 
familial risk is not yet observed). The method may therefore be better suited for studying 
childhood onset disorder like as ADHD, as compared to late-onset disorders. The 
appropriateness of estimating familial aggregation without or without considering time will 
vary based on previous knowledge regarding the temporal ordering of the disorders, age of 
disorder onset, and the observed follow-up time for the cohort.212  
Hudson et al.,213 has proposed a framework using directed acyclic graphs (DAG) to illustrate 
how the familial co-aggregation between two disorders may be estimated and interpreted under 
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specific disorder association conditions. Figure 5.1 shows a DAG of the hypothesized familial 
co-aggregation between ADHD (AD) and epilepsy (EP) as an example (Study 3 of this thesis). 
In this DAG, the parameter of interest is the latent factor FAD-EP, which represents shared 
familial causes contributing to disorder liability for AD and EP. By estimating all open paths 
to FAD-EP, a measure of the familial association can be obtained. Under the assumptions that 
there are no direct of one disorder on the other within the same person (depicted by the dashed 
arrows), estimation of the open path EP2 ←FAD-EP→AD1 (which is assumed to be symmetric 
with AD2 ←FAD-EP→EP1) will give an estimate of the familial co-aggregation between AD and 
EP. Nonetheless, in the presence of a direct effects of EP on AD (or vice versa), the additional 
path EP2 ←FEP→EP1 →AD1 will also be open. In this scenario, the total estimated familial 
association will be due to both FEP, which represent familial factors contributing to disorder 
liability in EP only, and FAD-EP. To isolate the effect of FAD-EP from FEP requires making several 
assumptions that are often not known, e.g., about the direction of effect between the disorders, 
distribution of the latent variables (e.g. FAD-EP), and whether the considered paths are likely to 
represent positive or negative association.213 The extent to which such assumptions are valid 
will differ depending on the disorders under study and prior knowledge. 
 
 
 
 
 
 
 
Figure 5.1. Directed acyclic graph depicting the hypothesized relations between ADHD (AD) 
and epilepsy (EP).  
Note: EP1 &2, Epilepsy in relative 1 and 2; AD1 & 2, ADHD in relative 1 and 2; FAD-EP:  Shared familial 
causes for ADHD and EP; FEP, familial causes unique for EP. FAD, familial causes unique for ADHD.C1, 
common causes for EP and ADHD specific to relative 1; C2, common causes for EP and ADHD specific 
to relative 2. Dashed arrows denote possible direct within-individual effects of EP on ADHD. 
In addition to showing familial aggregation, family studies including multiple types of relatives 
can also be used to infer the relative importance of genetic and family environmental factors 
for the disorder aggregation (Table 5.2). For example, if the strength of disorder association 
across relatives increases along with the increasing degree of genetic sharing, the importance 
of genetic factor for the disorder association can be assumed. In Study 3, we assessed the 
familial co-aggregation between ADHD and epilepsy across multiple types of relatives, based 
on life-time prevalence for both disorders. 
 
EP1 
 
FAD-EP
 
EP2 
 
AD2 AD1 
FEP
 
FAD
 
 
C2 C1 
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 Table 5.2. Assumed degree of genetic and environmental sharing across relatives 
 
Note: In parent-offspring pairs, 50% of segregating genes are shared, and in MZ pairs 100%. For other 
types of relatives, percentages refer to on average sharing for (autosomal) segregating genes. 
  
RELATIVE GENETIC SHARING ASSUMED ENVIRONMENTAL SHARING 
Mother-
offspring 
50% additive genetics  
0% dominant genetics 
 Mothers provide the in-utero and early rearing 
environment to their offspring. 
 A higher risk in mother-offspring, compared to father-
offspring, suggest a maternal-specific effect over and 
above shared familial factors. 
Father-
offspring 
50% additive genetics  
0% dominant genetics 
 
 Fathers provide the early rearing environment to their 
offspring. 
MZ twins 100% additive and 
dominant genetics 
 
 Environmental sharing is assumed to be 100%. 
 MZ twins also share in-utero environment. 
DZ twins 50% additive genetics 
25% dominant genetics 
 Environmental sharing is assumed to be 100%. 
 DZ twins also share in-utero environment. 
Full siblings 50% additive genetics 
25% dominant genetics 
 Environmental sharing is assumed to be 100%. 
 Share pregnancy related factors, constant in the mother 
across pregnancies. 
 A higher risk in full siblings pairs, compared to 
maternal half siblings, indicate the importance of 
genetic factors. 
 
Maternal 
half siblings 
25% additive genetics 
0% dominant genetics 
 Environmental sharing is assumed to be 100%. 
 Share pregnancy related factors, constant in the mother 
across pregnancies. 
 A higher in risk maternal, compared to paternal, half 
siblings indicates the importance of shared 
environmental factors, as they share their environment 
to a greater extent. 
Paternal  
half sibling 
25% additive genetics 
0% dominant genetics 
 Environmental sharing is <100%, and is assumed to be 
0%, as children tend to reside predominantly with 
mothers after parental separation, particularly early in 
life. 
Full cousins 12.5% additive  
0% dominant genetics 
 Environmental sharing is assumed to be 0%. 
 An observed risk across cousins provides strong 
support for the importance of genetic factors, since 
environmental sharing tends to be minimal across 
cousins. 
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5.2.1.2  Twin designs  
Twin studies are concerned with investigating genetic and environmental contributions to 
individual differences in complex human traits. The twin method can be considered a natural 
experiment that utilizes the different degree of genetic sharing between monozygotic (MZ) and 
dizygotic (DZ) twins to quantify the contribution of genetic and environmental factors to 
variance in a trait.214 MZ twins are genetically identical, whereas DZ twins share on average 
50% of their segregating genes. Under the assumptions that MZ and DZ twins share their 
environments to a very similar extent (from the prenatal environment to later environmental 
factors), a higher similarity within MZ twin pairs for the trait of interest, as compared to DZ 
twin pairs, may be interpreted as evidence for the genetic contribution to variation in the trait.214 
Similarity for a given phenotype within a twin pair is commonly estimated via intraclass 
correlations (ICC), and similarity across phenotypes by the cross-twin-cross-trait correlation 
(CTCT).   
Comparison of correlations across MZ and DZ pairs allows for the variance (𝑉) of a given trait 
to be decomposed into three latent factors:  Additive genetic effects (𝐴, additive across alleles) 
shared environmental effects (𝐶, all factors that contribute to similarity between family 
members beyond genetic resemblance), and non-shared environmental effects (𝐸, factors that 
contribute to dissimilarity among family members), which also includes measurement error. 
Dominant genetic effects (𝐷, interaction between alleles at the same gene locus) may also be 
estimated depending on the pattern of twin correlations.  Under assumption of no interaction 
and no covariance between A, D, C, and E, the total variance of a phenotype (𝑃) can be 
expressed as 
𝑉𝑎𝑟(𝑃) = 𝐴 + 𝐷 + 𝐶 + 𝐸 
Narrow sense heritability is defined as the proportion of variance in a trait due to additive 
genetic effects(𝐴), and broad sense heritability as the proportion of variance due to additive 
and dominance genetic effects(𝐴 + 𝐷)  
ℎ2 =
𝑉𝑎𝑟(𝐴 + 𝐷)
𝑉𝑎𝑟(𝑃)
 
The classical twin method can be extended to test for etiological differences between males 
and females, using sex-limitation models as in Study 1 of this thesis. It can also be extended to 
study bivariate and multivariate traits association, as in Study 1 and 3. 
5.2.1.3 Extended family designs  
Similar to the twin method, extended family designs aim to estimate unknown variance 
components (A, D, C and E) from known or assumed information regarding the degree of 
genetic and environmental sharing across different types of relatives.  
Extended family designs, have some advantages over the classic twin design. In the classical 
twin design, variance components A, C and D are mutually confounded and cannot be 
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estimated within the same model since three unknown parameters cannot be simultaneously 
estimated from only two pieces of information (the MZ and DZ covariance). Another common 
critique of the twin method is that twins are not representative of the general (singleton) 
population. Additionally, the study of relativity rare disorders measured categorically may not 
feasible in twin studies due to power limitation. By extending the classical twin design to 
include other types of relatives, simultaneous estimation of A, C, D and E is possible, and 
generalizability and statistical power is improved.215,216 As in the twin method, certain 
assumptions must be made regarding the degree of genetic and environmental sharing across 
relatives types (Table 5.2). Whereas the calculation of on average sharing of segregating genes 
is straightforward across relative types, assumptions regarding the degree of shared 
environment are more challenging. These need to be made on prior knowledge, for example of 
how relatives usually co-habit. Such assumptions are likely subject to some misspecification, 
the effect of which will vary depending on the trait(s) under study.142 In Study 3 of this thesis, 
we employed an extended sibling design, using data from full siblings and maternal and 
paternal half siblings, to estimate genetic and environmental contributions to the association 
between ADHD and epilispy.142,217 
5.2.2 Within-individual designs 
Within-individual designs are a type of genetically informative study designs that can be used 
to study exposure-outcome association, when the exposure varies over time and can be 
measured at across time-points. Although there are different flavors and estimation techniques 
of the within-individual design,36,218,219 the basic premise is that each individual acts as their 
own control, and the risk of the outcome is compared between exposed time periods (e.g. 
treatment) and unexposed periods (e.g., no treatment) within the same person. By doing so, the 
within-individual estimate is adjusted for confounding by all covariates that are constant within 
an individual during the follow-up (e.g. genetic predisposition, baseline disease severity, and 
environmental exposures preceding start of follow-up). This makes the within-individual 
comparison a powerful design for pharmacoepidemiological studies, particularly when large-
scale RCT’s are not feasible or ethical. Within-individual comparisons also enables the 
researcher to address the issue of confounding by indication or severity, i.e. when the indication 
for treatment is also associated with the outcome. The DAG in figure 5.2 depicts the issue, 
using Study 4 in this thesis as an example. We are interested in estimating the association 
between ADHD medication and the risk for epileptic seizures. However, ADHD, which is the 
indication for receiving ADHD medication, is also associated with epilepsy. In turn, the 
association between the disorders may be attributed to unknown or unmeasured (U) 
confounding factors that vary between individuals, e.g. shared genetic or environmental factors 
that increase the risk for both disorders. In Study 4, we address this issue by estimating the 
effect of ADHD medication on the risk of epileptic seizures, adjusting for U by using a within-
individual comparison design. 
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Figure 5.2. DAG depicting the hypohtesized association between ADHD medications and 
seizures 
5.2.3 Molecular genetic designs 
Molecular genetic designs differ from the above outlined genetically sensitive designs, in that 
actual measured genetic variation is used to study disease etiology, rather than inferred 
differences in genetic similarity across relatives. Molecular genetic designs include a wide 
range of study types, of which genome wide association studies (GWAS) and polygenic risk 
score (PRS) studies are of relevance to this thesis.  
Thanks to fast-paced methodological advances, extensive collaborative networks such as the 
Psychiatric Genomics Consortia (PGC), and nationwide bio-banking efforts like the Danish 
Neonatal Screening Biobank, large-scale GWAS are now commonplace and available for a 
wide breadth of human complex traits. The primary aim of GWAS is to identify common 
genetic variants (SNPs),  that are associated with a continuously measured trait or with an 
increased risk of a categorically defined disorder (0/1).220 As association is tested across million 
SNPs, a stringent p-value threshold is required for significance (generally p < 5 × 10−8). Thus, 
large sample sizes are required to have sufficient statistical power to detect significant 
associations. 221 Nevertheless, the utility of GWAS extends beyond the investigation of genome 
wide significant hits, and one of the most commonly used applications of GWAS results is 
polygenic risk prediction.220 
Polygenic risk score (PRS) provide a measure of individuals genetic liability for a given 
phenotype. To conduct a PRS study, two independent samples with genotype data are required; 
firstly, association results from a GWAS for the phenotype of interest is needed. This is 
commonly referred to as the discovery sample. Secondly, an independent sample with both 
genotype and phenotype data, into which the PRS prediction will be made, is needed. Risk 
alleles which show association with the phenotype of interest below a predefined p-value 
threshold in the discovery GWAS, and their corresponding effect sizes, are then used to derive 
a PRS for each individual in the independent target sample. PRS are calculated as the sum of 
the count of risk alleles weighted by their effect size (e.g. log odds ratio (OR) for case–control 
GWAS and z-scores or beta coefficients for continuous trait GWAS) in the discovery sample 
(Figure 5.3). 
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Figure 5.3.  Overview of method for deriving polygenic risk scores (PRS) 
As with all genetic analyses, population stratification must be considered; Ancestry outliers  
should be removed and PRS analyses need to be adjusted for ancestry by including principal 
components (PCs) derived from the genomic relationship matrix to account for genetic 
substructure of the data in the target sample.221 Further, PRS estimates will be biased upwards 
in case of any sample overlap between the discovery and the target sample.222 PRS prediction 
is usually assessed through regression analyses, estimating the association between the genetic 
liability for a given phenotype, as captured by the PRS, with the target phenotype, after 
accounting for covariates. In Study 2, we estimated the association between PRS for ADHD 
and a broad range of childhood psychiatric traits. 
5.3 STATISTICAL METHODS 
5.3.1 Structural equation modeling  
“When evaluating a model, at least two broad standards are relevant. One is whether the 
model is consistent with the data. The other is whether the model is consistent with the ‘real 
world.’” Kenneth A. Bollen, Structural Equations with Latent Variables (1989) 
Structural equation modeling (SEM) is a statistical framework to model covariance matrices 
that can be applied in wide array of analyses. SEM may be viewed as a combination of factor 
and regression analyses, were the interest lies in describing the latent (unmeasured) constructs 
which are assumed to underpin the observed data. The relationship between these latent 
construct are represented by regression or path coefficients. All SEM models can be expressed 
as a set of equations with a corresponding path diagram, which represent the modelled or 
expected covariance matrix. Model fit is then evaluated on how well the modelled covariance 
structure represent the observed covariance structure of the sample data. SEM models are very 
flexible and allow for the simultaneous estimation of multiple standard statistical models.223,224 
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SEM is often conducted using continuously measured variables, but can also be applied to 
analyze categorical traits by using liability threshold models. The observed binary or ordinal 
trait is then assumed to be underpinned by a continuous liability distribution in the population, 
with a fixed mean and variance. Individuals who present with symptoms exceeding a given 
threshold on this liability distribution are cases, and those below are non-cases. The level of 
the threshold is given by the life-time prevalence of the disorder in the population.212 It should 
be noted that analyses of categorical data using liability threshold models requires substantially 
larger sample sizes as compared to analyses of continuous traits. For twin analyses, 
approximately three times as many twin pairs are needed to reach equivalent power between 
categorical and continuous analyses if the threshold is 50%, and the ratio increases to roughly 
10:1 if the threshold is 10%.225 Liability thresholds models were used in Study 2 and 3 of this 
thesis to model ordinal symptom data and categorical diagnosis data, respectively. 
5.3.1.1 Quantitative genetic analysis using SEM 
Quantitative genetic models are commonly implemented in OpenMx, an open-source SEM 
package in the software R.226 In this thesis, OpenMx was used in Study 1 and 3 to estimate the 
latent genetic and environmental factors assumed to underpin variance in the measured traits 
of interest, and the covariance between them. The path diagram in Figure 5.4 depicts the 
bivariate Cholesky decomposition227 used in Study 3. The bivariate twin model simultaneously 
estimates the effects of the latent factors A, C and E to variation in both traits individually, and 
the extent to which genetic and environmental contributions are shared between the two traits. 
Latent factors A, C and E are represented as circles and the measured traits as rectangular 
boxes, presented for the two siblings in a pair. The double-headed arrows represent the assumed 
correlations across siblings in pair, based on sibling type. As E is by definition not shared 
between siblings, these latent factors are not correlated. Following path tracing rules,228 the 
expected variance and covariance for the two phenotypes can be estimated. Path coefficients 
a11, c11, e11 reflect variance unique to trait 1, and a22, c22, e22 reflect variance unique to trait two. 
Taking full-siblings as an example, the genetic effect contributing to the covariance between 
sibling 1 and sibling 2 on trait 1 are given by  
(𝑎11 ∗ 0.5 ∗ 𝑎11) = 0.5𝑎11
2  
and the genetic effects on trait 2 are given by 
(𝑎21 ∗ 0.5 ∗ 𝑎21) + (𝑎22 ∗ 0.5 ∗ 𝑎22) = 0.5𝑎21
2 + 0.5𝑎22
2  
The same principle is applied to estimate the paths for the latent factors C and E. The paths a21, 
c21, and e21, represent the covariance between ADHD and EP. To obtain the cross-trait 
correlation for A, C and E, the covariance between the traits is divided by the square root of 
the variance for each trait. For the genetic correlation (rg), this is given by 
𝑟𝑔( 𝐴𝐷𝐻𝐷1, 𝐸𝑃1) =  
𝑎11 ∗ 𝑎21
√𝑎11
2  ∗  (𝑎21
2  +  𝑎22
2 ) 
=
𝑎21
√𝑎21
2  +  𝑎22
2  
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Figure 5.4. Bivariate Cholesky decomposition for sibling data used in Study 3 
Note: Latent factors A, C and E are represented in circles, and are specific to ADHD (trait 1: A1, C1, E1) 
and epilepsy (trait 2: A2, C2, E2). Path coefficients (single headed arrows) are either unique to the ADHD 
(a11, c11, e11) and epilepsy (a22, c22, e22) or indicate the effect of latent factors related to ADHD, which 
also contribute to epilepsy (a21, c21, e21). The correlations between A and C are determined by the type 
of siblings pair (FS, full-siblings. MH, maternal half-sibling. PH, paternal half-siblings). 
Although the Cholesky decomposition227 implies a causal ordering between the variables, it 
can be transformed into a correlated factors solution which is a standardized version of the 
bivariate Cholesky, where the order of the two variables is irrelevant, and arrows between latent 
factors are bi-directional.227 This was done in Study 3, where results were interpreted and 
presented as a bivariate correlated factor model. 
5.3.1.2 Factor analysis using SEM 
Factor analysis (FA) is a statistical technique which aims to uncover the underlying latent 
factors that gave rise to the covariance structure among a set of observed variables. Within FA, 
there is exploratory and confirmatory FA. Whilst the first is an exploratory analysis to 
understand the clustering of variables based on the observed covariance matrix, the latter is a 
confirmatory technique where a hypothesized model is used to estimate a covariance matrix 
that is then compared to the observed covariance matrix in the sample data. Model fit is 
evaluated based on the difference between the estimated and observed matrices. Each latent 
variable in a CFA is measured by a set of observed indicator variables, which are the measured 
variables. A simplified path diagram of the CFA in Study 2 is given in section 6.2.2. FA is 
commonly estimated by SEM, using a similar method as described above. However, because 
quantitative genetics and FA come from different research traditions, FA is often implemented 
using other SEM software, such as Mplus.229 It should be noted, that FA techniques rely on 
many decision that are largely pragmatic, and not necessarily driven by theory or firm prior 
knowledge. The number of extracted latent factors, rotations used, specification of correlations 
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across latent factors, and the interpretation of factors will have implications for the validity of 
the modelled factor structures. Cross-validation of is therefore a key issue in FA, and more 
generally for SEM models.  
In Study 2 of this thesis, we used SEM to combine CFA and multiple regression. The 
measurement part of the model constituted the CFA, where the latent factor assumed to give 
rise to the observed correlations across measures of childhood psychopathology were defined. 
In the structural part of the model, the regressions between ADHD PRS and the latent variables 
were estimated.  
5.3.1.3 Model fit in SEM 
Several goodness-of-fit statistics may be used to estimate the fit of a SEM model (i.e., how 
well the model explains the underlying data structure), and to compare the goodness-of-fit 
across multiple models. The choice of fit statistic should be guided by the complexity of the 
model, and the distribution and sample size of the data to which the model is applied. 
Maximum Likelihood estimation (MLM), which uses all available information are commonly 
used in SEM to test the probability of observing the sample data, given the specified parameters 
of the SEM model. Model comparison between nested models may be done using the 
likelihood ratio test, where the change in minus twice the log-likelihood (-2LL) follows a χ2-
distribution, with difference in number of parameters being the number of degrees of freedom. 
In general, more parsimonious models are preferred, as indicted by a non-significant change in 
the -2LL for the more restricted (nested) model. With large sample size, the likelihood ratio 
test is sensitive, and even small changes in model fit may results in a significant change for the 
-2LL (although this is an area of debate). Thus, other fit-statistics such the Bayesian 
Information Criterion (BIC),230 which was used in Study 1 of this thesis, can be used to aid 
model selection. BIC has been shown to be more robust to distributional misspecification and 
to outperforms other fit statistics in larger samples and when comparing more complex 
models.231 A lower BIC indicates better fit, taking into account the complexity of the proposed 
models (i.e. the number of parameters in the model) as well as the sample size.230  
Whilst the likelihood ratio test and BIC are commonly used in quantitative genetic SEM, other 
goodness-of-fit statistics are often reported for CFA. In this thesis, we relied on the root mean 
square error of approximation (RMSEA) and the comparative fit index (CFI) to assess model 
fit in Study 2. RMSEA is an absolute fit index that assess how well the model fits the sample 
data in comparison to no model at all, taking parsimony into account. Better model fit is 
indicated by lower RMSEA. It has been suggested that a RMSEA statistic of ≤ 0.06 is needed 
to indicate good model fit.232 The CFI also is commonly used as it is not greatly affected by 
sample size. The CFI statistic evaluates the model by comparing the χ2 value of the model to 
the χ2 of a null model, where all latent variables are specified as uncorrelated. A cut-off criterion 
of CFI ≥ 0.95 is suggested to indicate good fit.232  
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5.3.2 Regression models  
Regression models included in this thesis include the Cox Proportional Hazard Model 
(discussed below) and different types of generalized linear models (GLM). GLM are widely 
used for estimation of exposure-outcome associations, with the possibility to conduct statistical 
adjustment for other covariates. GLM provides a flexible framework where an outcome is 
associated with covariates (including the exposure) through a link function. The choice of link 
function (and the assumed underlying distribution) determines on which scale inferences are 
made. A GLM may be expressed as 
𝑔(𝐸(𝑌𝑖|𝑥𝑖)) =  𝒙𝒊
𝑻𝜷 = 𝛽0 + 𝛽1𝑥𝑖1 + 𝛽2𝑥𝑖2 + ⋯,   
where 𝑔(⋅) is the link function, 𝐸(𝑌𝑖|𝑥𝑖) is the expected value of the outcome 𝑌𝑖, for 
observation 𝑖 , given the vector of covariates 𝑥𝑖 and 𝜷 is a vector of regression coefficients. In 
this thesis, the following link functions were used; identity (linear regression for continuous 
outcomes in Study 2, with the associations expressed as regression coefficients), logit (logistic 
regression for binary outcome in Study 3, with the associations expressed as odds ratios [OR]) 
and log (Poisson regression for count outcomes in Study 4, with the associations expressed as 
incidence rate ratios [IRR]). In general terms, the estimated coefficient in GLM are interpreted 
as the change in the outcome (interpreted on the scale for which is was estimated; e.g. log-odds 
for the OR) for every unit change in the exposure, holding all other covariates constant.   
A few things should be noted for the specific regression models used: 
 In logistic regression models in cohort studies were the outcome is rare, the OR will 
approximate the risk ratio, and can be interpreted as such. Logistic regression was used 
in Study 3 to estimate OR of ADHD case status among relative of individuals with 
epilepsy and we interpreted the OR as a relative risk. 
 
 In Poisson regression, one can explicitly model differing time of follow-up, to estimate 
rates per time unit. This is achieved by including an offset term in the regression model, 
thus estimating rates as the  number of events per time unit specified. Poisson regression 
was used in Study 4 to estimate the IRR of seizures in different time-bands prior and 
post ADHD medication initiation, accounting for time by including an offset for the 
number of weeks in each time-band. 
5.3.2.1 Cox proportional hazards regression  
Cox proportional hazards regression are used for analyzing time to event, or survival, data. The 
interest lies in the hazard,  ℎ(𝑡) of an event at time 𝑡, as a function of the baseline hazard and 
a set of the covariates (including the exposure) 
ℎ(𝑡) =  ℎ0(𝑡)𝑒𝑥𝑝(𝛽1𝑥𝑖1 + 𝛽2𝑥𝑖2 + ⋯,  
where ℎ0(𝑡) is the baseline hazard at 𝑡𝑖𝑚𝑒 = 𝑡, for a person with 0 on all covariates. In this 
model, no assumptions are made about the shape of baseline hazard, and it is never explicitly 
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estimated. However, it is assumed that the hazards are proportional throughout follow-up 
across the different level of covariates (e.g. exposed and unexposed), which may be a very 
strong assumption.233 Proportionality of hazards across time should therefore be assessed, e.g. 
via visual inspection of the Schoenfeld residuals. The Cox model is appealing due to the very 
efficient adjustment for underlying time-scale, especially when the selected time-scale may 
potentially confound the association of interest, and because time-varying covariates may be 
modeled. The choice of underlying time-scale will depend on the research question (e.g. if the 
outcome is strongly correlated with attained age, this should use this as the underlying 
timescale). In Study 4, we used Cox proportional hazards regression to estimate the hazard 
ratio of epileptic seizures during ADHD medicated compared to non-medicated periods, with 
time since last seizure at the underlying time-scale.  
5.3.2.2 Clustered data in regression models 
An assumptions of most statistical tests is the independence of observations for the outcome, 
given the included covariates. In this thesis, we rely on correlated data where this assumption 
is likely to be violated (i.e. twin and family data, repeated observations from the same 
individual). As a results, standard errors of the estimated regression coefficients may be biased. 
This can be addressed using different statistical or methodological techniques. For between-
cluster analyses (population-level) the issue may be addressed using methods that produce 
cluster robust standard errors, such as the sandwich formula or bootstrap sampling 234,235. The 
sandwich estimator accounts for model misspecifications due to data clustering and was used 
in Study 2-4 of this thesis to generate so-called robust standard errors. Nonparametric bootstrap 
sampling was used in the quantitative genetic analyses in Study 3, by repeatedly drawing (with 
replacement) families, re-computing the model estimates in 1000 bootstrap samples, and 
estimating standard errors from the distribution of the bootstrap replicates. In within-cluster 
analyses, the clustering of the data is not a threat to the validity of the study, but can instead be 
used to condition the analyses on the cluster (i.e. repeated measures from the same individual) 
as a means to control for unmeasured cluster-constant confounding. In Study 4, we used 
Conditional Poisson and Stratified Cox regression in order to control for time-constant factors 
within the same individual, by entering each individual into the model as a separate stratum.236 
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6 STUDY SUMMARIES AND RESULTS  
6.1 ADHD AND RELATIVE IMMATURITY (STUDY 1)  
6.1.1 Rationale 
Study 1 is a classical twin study investigating the etiological overlap between parent’s 
perceptions of their child’s immaturity relative to peers (RI) in childhood, with the development 
of ADHD symptoms from childhood to early adulthood. Specifically, this study aimed to 
address two questions;  
I) Is RI in childhood associated with ADHD symptoms across development and does 
this assocation decrease with increasing age? 
II) To what extent can an observed assocation between RI and ADHD across 
development be explained by shared genetic factors? 
6.1.2 Method 
Parent-ratings of RI at ages 8-9 years and parent- and self-ratings of ADHD symptoms (AP; 
measured via the attention problems ASEBA scales) at ages 8-9, 13-14, 16-17 and 19-20 years 
for 1,302 twin pairs from TCHAD were used. A longitudinal twin model with multiple raters 
(parent- and self-ratings)237 was used to estimate the relative contribution of genetic and 
environmental factors to covariance between RI and AP across ages (Figure 6.1.1). 
Figure 6.1.1 Path diagram of the longitudinal, multi-rater model, presented for one twin and 
one source of variance, such as additive genetic effects  
 
Note: The model contained 5 latent trait factors; 1 for relative immaturity at ages 8 to 9 years (RI1) and 
4 for attention problems (AP1–AP4), reflecting the “shared” view of AP at each age. Latent variables 
were indexed by parent-ratings (P) and twin self-ratings (S) when available. The degree to which parent- 
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and self-ratings index the latent factors is reflected by the paths 𝜆𝑝 and 𝜆𝑠. FP and FS reflect rater-specific 
latent common factors for parent- and self-ratings of AP. RP and RS refer to rater- and time-specific 
residuals for parent- and self-ratings of AP. The genetic and environmental influences on RI1 and AP1 
to AP4 were modeled using Cholesky decomposition,227 with RI1 preceding AP1 to AP4. Taking genetic 
contributions as an example, F1 reflect RI-related genetic effects that contribute to variance in RI1 (8–9 
years) via path f11. In addition, F1 explains variance in AP at all ages through paths f12, f13, f14, and f15. 
The second factor (F2) reflects AP-related stable genetic effects that contribute to variance in AP at aged 
8 to 9 years, over and above any variance explained by RI1, and contributes to genetic stability in AP 
through paths f22, f23, f24, and f25. F3-F5 are interpreted in a similar way, reflecting new genetic factors 
that come online at each age, influencing variance in AP. The factor structure depicted by F1 to F5 was 
implemented for the 3 sources of variance: A, C or D, and E. The figure is adapted from Kendler K, et 
al., 2008.237 
6.1.3 Results 
Phenotypic associations  
Findings from Study 1 revealed significant phenotypic associations between RI in childhood 
and elevated AP throughout childhood and adolescence (Table 6.1.1). Associations across all 
ages were small to moderate, generally declined with age, and were stronger across RI and 
parent-rated AP (r=0.11-0.33), compared to RI and self-rated AP (r=-0.01-0.14) which were 
no longer significantly associated at age 19-20 years. 
Table 6.1.1 Pearson’s correlations between RI and AP across rater and time 
Age (y)     8-9 13-14 16-17 19-20 
  Rater   Parent  Parent Self Parent Self Parent Self 
      RI AP AP AP AP AP AP AP 
8-9 Parent RI 1.00 0.33 0.29 0.14 0.21 0.11 0.11 -0.01* 
Parent AP   1.00 0.54 0.25 0.45 0.17 0.39 0.09 
13-14 Parent AP     1.00 0.38 0.61 0.29 0.49 0.20 
Self AP       1.00 0.32 0.54 0.28 0.38 
16-17 Parent AP         1.00 0.39 0.55 0.18 
Self AP           1.00 0.28 0.45 
19-20 Parent AP             1.00 0.32 
Self AP               1.00 
*Non-significant correlations; All other correlations significant at p < 0.001. 
Twin analyses results 
Twin correlations (not shown) within trait, and across trait and time, where higher in MZ twin 
pairs than DZ in twin pairs, suggesting that genetic factors contributed to variance and 
covariance between RI and AP, as well as to the  associations in AP across ages. An AE model 
with no sex differences provided the best fit to the data. RI-related genetic effects (A1) 
explained 86% of the variance in RI at ages 8-9. Further, 10% to 14% of the variance in AP 
during childhood and adolescence could be explained by etiologic (genetic and environmental) 
factors related to RI, with a stronger contribution of genetic factors. The association between 
RI and AP decreased substantially from late adolescence (ages 16-17) to early adulthood (ages 
19-20), where RI-related etiological factors explained only about 4% of the variance in AP. 
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Non-shared environmental effects (E1) related to RI showed a similar pattern of association 
with AP, but were of smaller magnitude. In contrast, AP-related stable genetic effects (A2) 
explained 52% of the variance in AP at aged 8-9 years and continued to explain 30%, 26%, 
and 19% of the variance in AP at ages 13-14, 16-17, and 19-20 years. In addition to showing 
considerable genetic stability, new AP-related genetic effects came online throughout 
development. Standardized parameter estimates from the AE model are presented in Table 
6.1.2 and the % total variance explained in AP across ages in Figure 6.1.2. 
In line with previous findings in the TCHAD,106 the cross-rater latent factors (AP1–AP4) 
contributed more to parent-rated than to self-rated AP at assessment waves where both types 
of ratings were available. Rater-specific common factors contributed more toward self-rated 
AP than toward parent-rated AP, and a larger proportion of self-rated AP was modeled as rater- 
and time-specific residuals, as compared with parent-rated AP. 
Figure 6.1.2. Proportion of total variance in attention problems (AP) explained by genetic and 
non-shared environmental factors across development.  
 
Note: The y-axis represents the total phenotypic variance in AP accounted for by (A) genetic factors 
and (B) non-shared environmental factors. Relative immaturity (RI) corresponds to RI-related etiologic 
factors (F1 in Figure 6.1.1) at age 8-9 years, and AP corresponds to AP-related etiologic factors across 
ages (F2–F5 in Figure 6.1.1). 
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Table 6.1.2. Standardized parameter estimates for the genetic and environmental factors (F1-
F5 in Figure 6.1), together with percentage of the total variance in each factor explained by A 
(h2) and E (e2). 
  Genetic Parameter Estimates 
Factor             
age (y) 
Total 
h2 A1 A2 A3 A4 A5 
RI                
8-9 
86% 0.93         
(0.91-0.94)         
86%         
AP                  
8-9  
58% 0.26 0.72       
(0.20-0.33) (0.68-0.77)       
7% 52%       
AP                   
13-14  
84% 0.30 0.55 0.67     
(0.23-0.36) (0.48-0.61) (0.62-0.72)     
9% 30% 45%     
AP                  
16-17  
78% 0.27 0.51 0.44 0.50   
(0.20-0.34) (0.42-0.59) (0.35-0.53) (0.41-0.58)   
7% 26% 20% 25%   
AP                           
19-20  
77% 0.17 0.44 0.30 0.45 0.51 
(0.09-0.25) (0.34-0.54) (0.19-0.40) (0.30-0.60) (0.33-0.64) 
3% 19% 9% 20% 26% 
  
  Non-shared Environmental Parameter Estimates 
 Factor             
age (y) 
Total 
e2  E1 E2 E3 E4 E5 
RI                
8-9 
14% 0.38         
(0.35-0.42)         
14%         
AP                  
8-9  
42% 0.20 0.61       
(0.14-0.27) (0.56-0.66)       
4% 37%       
AP                   
13-14  
16% 0.22 0.18 0.29     
(0.15-0.28) (0.12-0.30) (0.20-0.37)     
5% 3% 8%     
AP                  
16-17  
22% 0.17 0.04 0.40 0.16   
(0.10-0.24) (-0.05-0.15) (0.30-0.50) (-0.01-0.31)   
3% 0% 16% 3%   
AP                           
19-20  
23% 0.08 0.09 0.25 -0.39 0.00 
(-0.01-0.17) (0.01-0.20) (0.10-0.40) (-0.54-0.14) (-0.49-0.49) 
1% 1% 6% 15% 0% 
              
Note: A1 to A5 and E1 to E5, latent factors presented separately for genetic and non-shared 
environmental effects. 95% profile likelihood CIs are presented in parentheses. AP, attention problems; 
e2 total proportion of variance explained by non-shared environmental factors; h2 total proportion of 
variance explained by genetic factors; RI, relative immaturity
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6.2 GENETIC RISK FOR ADHD AND ASSOCATIONS WITH RELATED 
CHILDHOOD PSYCHOPHATOLOGY (STUDY 2) 
6.2.1 Rationale 
Study 2 is a PRS study conducted in a large population based twin cohort, investigating the 
associations between ADHD PRS and a broad range of childhood psychiatric traits. 
Specifically, this study aimed to; 
I) Examine whether ADHD PRS is associated with a range of neurodevelopmental, 
externalizing, and internalizing psychiatric traits in childhood.  
II) Quantify the extent to which any observed associations between ADHD PRS and 
the aforementioned trait dimensions can be attributed to a general psychopathology 
factor. 
6.2.2 Method 
Study 2 used parent-ratings in CATSS of neurodevelopmental (IA, H/I, ASD, LD), 
externalizing (ODD, CD), and internalizing symptoms (DEP, ANX). Analyses were run 
separately across two subsamples, based on the available assessment of internalizing items. A 
total of 6603 twins (3483 unrelated individuals) were available for analysis in the A-TAC 
subsample, and 6854 twins (3634 unrelated individuals) in the SMFQ/SCARED subsample. 
ADHD PRS estimation 
ADHD PRS were generated in CATSS, using summary statistics from a meta-analysis (MA) 
of the two largest available GWAS of clinical ADHD and ADHD symptoms.59,60 
Standardized betas were calculated for each SNP, based on available information of z-scores, 
effective sample size and allele frequency in the ADHD GWAS-MA.238 ADHD PRS were 
derived in CATSS from best-guess imputed genotypes across seven p-value thresholds 
(0.00001≤PT ≤1). Indels, multi-allelic and symmetric/ambiguous SNPs were excluded. 
Autosomal SNPs with a minor allele frequency (MAF)≥0.05 and good imputation quality 
(INFO score)≥0.8 were clumped (linkage disequilibrium threshold R2 > 0.1,±1000 kb) to 
obtain an independent set of variants, using PLINK.v.1.9.239 Retained reference alleles were 
scored across the set of SNPs in PLINK using standard procedures.137 PRS including SNPs at 
a threshold of PT ≤0.50 were used for the main analysis, in line with previous publications.65,80 
Statistical analysis 
Associations between ADHD PRS and neurodevelopmental, externalizing, and internalizing 
traits were estimated using SEM. A CFA was fit to all measured symptom items, using two 
different models (Figure 6.2.1). We first fitted a correlated factors model where symptoms 
from each scale were set to load onto a corresponding single latent trait factor, and all latent 
factors were allowed to correlate. Second, a general psychopathology factor model was fitted, 
which in addition to the aforementioned latent trait factors, included a general 
psychopathology factor on which all symptom items loaded. A general factor model quantifies 
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the extent to which covariance among symptom dimensions reflects both a general factor (on 
which all assessed symptoms load) and a number of more specific factors (on which only a 
subset of the symptoms load). Correlations between the specific latent factors and the general 
factor are fixed at zero, whereas correlations between the specific latent factors are free to 
vary. In both models, the latent factors were regressed on ADHD PRS, with sex, age and the 
first six PCs (to account for possible population stratification) included as covariates. 
Analyses were conducted using Mplus.229 
Figure 6.2.1.  Path diagram of the general factor model, presented by study subsample  
 
Note: General factor model in the A-TAC subsample (A) and SMFQ/SCARED subsample (B). Latent 
factors are depicted as circles. The models consisted of a latent general psychopathology factor (GP) 
and specific latent trait factors reflecting symptoms of inattention (IA) hyperactivity/impulsivity 
(H/I), autism spectrum disorder (ASD), learning difficulties (LD), oppositional defiant disorder 
(ODD), conduct disorder (CD), depression (DEP) and anxiety (ANX) or panic disorder (PD), 
generalized anxiety (GAD), separation anxiety (SAD), school anxiety (SA), and social phobia (SP). 
Variances for all latent factors were fixed at 1. Measured variables are depicted as squares, and include 
the ADHD PRS and all symptoms items from A-TAC, SCARED and SMFQ, with 1…X indicating 
the number of symptom items loading onto each specific latent trait factor. β1-βx represent the 
regression coefficients, regressing each latent variable onto ADHD PRS. For clarity, covariates (age, 
sex and six PC’s) and correlations across latent trait factors are omitted in the above graphical 
representation 
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6.2.3 Results 
Model fit and loadings 
The correlated factor model fit the data well in both subsamples (CFI>0.94, RMSEA<0.02) 
(Table 6.2.1). All symptoms loaded positively and significantly onto their corresponding latent 
trait factor (Table 2, Manuscript 2). The general factor model also fit the data well in both 
subsamples (CFI>0.96, RMSEA<0.02). Furthermore, omitting the general psychopathology 
factor resulted in a statistically significant decrease in model fit based on the likelihood ratio 
test (Table 6.2.1). In the general factor model, all symptoms loaded positively and significantly 
onto the general psychopathology factor (Table 2, Manuscript 2). Mean loadings on the general 
psychopathology factor were strongest for neurodevelopmental traits, somewhat lower for 
externalizing traits, and weakest for internalizing traits. The general factor explained 56% of 
the covariance across traits (explained common variance [ECV]) in the A-TAC subsample and 
40% in the SMFQ/SCARED subsample. 
Table 6.2.1. Model fit for the correlated factor model and the general factor model 
Model CFI RMSEA (95%CI) χ2 (df) Δχ2 Δdf p 
A-TAC subsample  
GF 0.97 0.02 (0.02-0.02)  6674.06 (2216) - - - 
CF 0.95  0.02 (0.02-0.02) 8636.54 (2287) 1962.48 71 < .0001 
SMFQ/SCARED subsample  
GF 0.96 0.01(0.01-0.01)  12544.05 (5275) - - - 
CF 0.94 0.02 (0.02-0.02)  16123.77 (5382) 3579.72 107 < .0001 
Note: GF, general factor model. CF, correlated factor model. CFI, comparative fit index. RMSEA, root 
mean square error of approximation. χ2, Chi-square. df, degrees of freedom. The likelihood ratio test 
was run using the DIFFTEST option in MPlus, comparing the fit of the nested correlated factor model 
to the general factor model. 
ADHD PRS regression results 
In the correlated factor models, higher ADHD PRS were statistically significantly associated 
with higher symptom levels for all the latent neurodevelopmental, externalizing and depression 
trait factors, after adjusting for covariates (Table 6.2.2) ADHD PRS was not statistically 
significantly associated with the latent anxiety factors, with the exception of panic disorder 
(β=0.06, p=0.014). In the general factor models, higher ADHD PRS were significantly 
associated with higher scores on the general psychopathology factor (β=0.09-0.10, p<0.0001), 
explaining ~1% of the variance in the general psychopathology factor. After accounting for 
covariance across all symptoms via the general factor, only the association between ADHD 
PRS and the specific hyperactivity/impulsivity factor remained significant in both subsamples 
(β=0.06-0.08, p<0.0001), explaining 0.37-0.69% of the variance. Somewhat surprisingly, 
ADHD PRS also showed a significant negative correlation with specific social phobia (β=-
0.05, p=0.004) in the SMFQ/SCARED subsample. This may be explained by the latent SP 
factor showing a significant negative correlation with IA and H/I in the general factor model, 
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even prior to regression of the latent variables on ADHD PRS (results shown in supplementary 
materials of Manuscript 2). Results were consistent across p-value thresholds (Figure 6.2.3). 
 
Table 6.2.2. Association between ADHD PRS and latent trait factors in the correlated factor 
model and the general factor model (PRS p-value threshold≤0.5) 
Correlated Factors Model General Factor Model 
 Beta S.E p R
2 Beta S.E p R2 
A-TAC subsample (N= 6603) 
GP na na na na 0.09 0.02 <.0001 0.86% 
IA 0.09 0.02 <.0001 0.83% -0.01 0.02 .929 0.00% 
H/I 0.11 0.02 <.0001 1.19% 0.06 0.02 .003 0.37% 
ASD 0.07 0.02 <.0001 0.50% -0.01 0.03 .862 0.00% 
LD 0.07 0.02 <.0001 0.53% -0.01 0.03 .873 0.00% 
ODD 0.06 0.02 <.001 0.41% 0.01 0.02 .895 0.00% 
CD 0.08 0.03 .007 0.69% 0.03 0.04 .390 0.12% 
DEP 0.05 0.02 .009 0.26% -0.01 0.02 .564 0.01% 
ANX 0.05 0.02 .053 0.22% 0.00 0.03 .998 0.00% 
         
SCARED/SMFQ Subsample (N=6854) 
GP na na na na 0.10 0.02 <.0001 1.06% 
IA 0.10 0.02 <.0001 1.08% 0.02 0.02 .482 0.02% 
H/I 0.13 0.02 <.0001 1.69% 0.08 0.02 <.0001 0.69% 
ASD 0.06 0.02 .001 0.40% -0.03 0.02 .220 0.08% 
LD 0.07 0.02 .002 0.45% -0.03 0.03 .308 0.08% 
ODD 0.10 0.02 <.0001 0.98% 0.04 0.02 .058 0.17% 
CD 0.11 0.03 <.0001 1.19% 0.05 0.03 .117 0.26% 
DEP 0.07 0.02 <.001 0.42% 0.02 0.02 .411 0.03% 
PD 0.06 0.03 .014 0.41% 0.02 0.03 .405 0.05% 
GAD 0.03 0.02 .066 0.10% -0.01 0.02 .450 0.02% 
SAD 0.01 0.02 .826 0.00% -0.03 0.02 .071 0.10% 
SA 0.00 0.03 .996 0.00% -0.05 0.03 .052 0.27% 
SP -0.02 0.02 .272 0.04% -0.05 0.02 .004 0.24% 
Note: All models were adjusted for sex, age and six principal components. Beta, standardized regression 
coefficients. S.E, standard error. R2, variance explained (beta2). IA, inattention factor. H/I, 
hyperactivity/impulsivity factor. ASD, autism spectrum disorder factor. LD, learning difficulties factor. 
ODD, oppositional defiant disorder factor. CD, conduct disorder factor. DEP, depression factor. ANX, 
anxiety factor. PD, panic disorder factor. GAD, generalized anxiety disorder factor. SAD, separation 
anxiety disorder factor. SA, school anxiety factor. SP, social phobia factor. 
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Figure 6.2.3. Variance explained by ADHD PRS in latent factors from the correlated factor 
model (A) and the general factor model (B) across PRS p-value thresholds  
 
Note: Panel A, correlated factor model A-TAC subsample. Panel B, general factor model A-TAC 
subsample. Panel C, correlated factor model SMFQ/SCARED subsample. Panel D, general factor 
model SMFQ/SCARED subsample. R2= beta2. 
6.3 COMORBIDITY BETWEEN ADHD AND EPILEPSY (STUDY 3) 
6.3.1 Rationale  
Study 3 is a nationwide register-based family study investigating the underlying causes of 
comorbidity between ADHD and epilepsy. Specifically, this study aimed to; 
I) Investigate the familial co-aggregation of ADHD and epilepsy across multiple 
types of relatives. 
II) Estimate the contribution of genetic and environmental risk factors to comorbidity 
between ADHD and epilepsy. 
6.3.2 Method 
A study population of 1,899,654 individuals born in Sweden between 1987 and 2006 was 
identified via multiple national Swedish registers. Each individual in the cohort was in turn 
linked to their relatives using the MGR. Individuals who died or migrated prior to age seven, 
who were adopted, or whose biological parents were not identifiable were excluded. ADHD 
and epilepsy cases were identified based on discharge diagnosis in the NPR. Further ADHD 
cases were identified in PDR based on ADHD medication prescription. Information on case 
status was collected from age 3 until December 31, 2013.  
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Familial co-aggregation and quantitative genetic analyses 
Familial co-aggregation was estimated in each relative cohort using logistic regression, 
comparing the risk of ADHD in individuals with a relative with epilepsy, to the risk in 
individuals without a relative with epilepsy, adjusting for birth year and sex. Genetic and 
environmental contributions to the association between ADHD and epilepsy were estimated by 
fitting a bivariate extended sibling model (see section 5.3.1.2) to data from all pairs of full 
siblings, maternal and paternal half siblings in the cohort. Parent-offspring pairs were not 
included due to changes in diagnostics practices and differential coverage of the registers across 
the two generations. The model was fit using the weighted least squares method and standard 
errors were obtained using nonparametric bootstrap sampling to account for the non-
independence of sibling data. Analyses were implemented in OpenMx.226  
6.3.3 Results 
Familial co-aggregation results 
Individuals with epilepsy had a statistically significant increased risk of ADHD, compared with 
individuals without epilepsy. Further, relatives of individuals with epilepsy also had 
statistically significant increased risk of ADHD, and the strength of association increased along 
with increasing relatedness (Figure 6.3.1). The association was significantly higher for mother-
offspring pairs, compared to father-offspring (p=.004), and for maternal half siblings, 
compared to paternal half siblings, for whom the risk increase was not statistically significant. 
Figure 6.3.1. Within-individual and familial co-aggregation of ADHD and epilepsy
 
Note: Odds ratios (ORs) represent the association between ADHD and epilepsy within-individual and 
across different types of relatives. ORs are adjusted for birth year and sex. The 95% confidence intervals 
(CI) are presented in parentheses.  
Quantitative genetic results 
The phenotypic correlation between ADHD and epilepsy was estimated at 0.24 (95% CI = 
0.23–0.25) in the sibling cohort (N=1 186 306 sibling pairs). Sibling correlations were higher 
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in full siblings than in maternal half siblings, indicating the contribution of genetic factors to 
variance and covariance between liabilities for ADHD and epilepsy (Table 6.3.1). Furthermore, 
all correlations were somewhat higher in maternal half siblings, than in paternal half siblings, 
indicating a possible contribution of shared environmental factors. This is because both types 
of half siblings share 25% their segregating genes, but maternal half siblings tend to share more 
environmental factors, especially early in life.240 There was no indication of dominance genetic 
effects which are indexed by maternal half-sibling correlations being less than half of the full 
sibling correlations. 
Table 6.3.1. Intra-class (ICC) and cross-trait-cross-sibling (CSCT) correlations between 
ADHD and epilepsy 
Note: Concordant pairs refers to the number of sibling pairs where one sibling had a diagnosis of 
epilepsy and the other sibling had a diagnosis of ADHD. 95% CIs are presented in parentheses. 
Based on the observed sibling correlations, an ACE model was fitted. Results showed that 
genetic and shared environmental factors together explained 51% of the phenotypic correlation 
between epilepsy and ADHD (additive genetic contribution = 40%, 95%CI=9-70; shared 
environmental contribution = 11%, 95%CI=-3-25). Remaining covariance (49%, 95%CI=32-
67) was attributable to non-shared environmental factors (Figure 6.3.2). 
Figure 6.3.2. Path diagram for the bivariate ACE model, estimating the genetic and 
environmental correlations between ADHD and epilepsy     
Note: Values within the square root sign are the squared path coefficients and represent the % variance 
accounted for by A, C, and E for each trait. Curved double-headed arrows represent to the correlation 
between A, C, and E across liabilities for ADHD and epilepsy. 95% CI presented in parentheses. 
  N Pairs 
Concordant 
Pairs ICC ADHD ICC EP CSCT  
Full 
siblings 914 842 598 
0.45  
(0.44-0.45) 
0.24  
(0.22-0.26) 
0.08  
(0.06-0.09) 
Maternal 
half siblings 136 962 198 
0.26  
(0.24-0.27) 
0.17  
(0.12-0.22) 
0.04  
(0.01-0.07) 
Paternal     
half siblings 134 502 150 
0.19  
(0.17-0.20) 
0.07 
(0.02-0.13) 
0.01 
(-0.02-0.05 ) 
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6.4 SAFETY OF ADHD MEDICATIONS IN INDIVIDUALS WITH A SEIZURE 
HISTORY (STUDY 4) 
6.4.1 Rationale  
Study 3 is a nationwide register-based pharmacoepidemiological study, investigating the risk 
of seizures associated with ADHD medication use in individuals with a seizure history, with 
and without comorbid NDDs. Specifically, we aimed to investigate; 
I) Whether the time around incident ADHD medication treatment is associated with an 
increased risk of seizures? 
II) Whether repeated ADHD medication periods are associated with an increased risk of 
seizures? 
6.4.2 Method 
Individuals born in Sweden between 1968 and 2007, who had experienced a seizure before age 
30 according to discharge diagnoses in the NPR, were included. All individuals were followed 
from January 1, 2006, their first seizure or age five, whichever came last, until December 31, 
2013 or death, which ever came first. Individuals who migrated during follow-up were 
excluded, resulting in a study population of 44,827 individuals, representing 80% of the study 
base. ADHD medication periods identified via the PDR were treated as a time-varying 
exposure, and seizure events identified in NPR as the outcome. See section 4.3.1.3- 4.3.1.5 for 
details on definitions of exposure, outcome, and covariates. 
Incident medication analyses 
Incident ADHD medication dispensation was defined as a dispensation of ADHD medication 
preceded by at least 18 months without a dispensation. The rate of seizures during the 24 weeks 
before and after ADHD medication initiation were compared with the average rate during the 
same 48 weeks in the previous year. Follow-up time was split into 0-4, 5-12 and 13-24 weeks 
pre- and post-medication initiation. Incidence rate ratios (IRR) were estimated using 
conditional Poisson regression, entering each individual as a separate stratum to adjust for 
confounding by unmeasured covariates that are constant within-individual during follow-up. 
Repeated medication analyses 
Cox proportional hazards models were used to estimate the population-level association 
between repeated ADHD medication periods (time-varying exposure) and the rate of seizure 
events, using robust standard errors to account for the non-independence of data. Population 
level analyses were adjusted for sex, age and concomitant AED medications. Stratified Cox 
proportional hazards models were used to estimate the within-individual association between 
ADHD medication periods and the rate of seizure events, entering each individual as a separate 
stratum in the model. These models were explicitly adjusted for categorical age and 
concomitant AED use. We further re-ran analyses among individuals with an ADHD diagnosis, 
and stratified the analysis on the presence or absence of additional NDDs. 
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6.4.3 Results 
Incident medication analyses 
Within the study population, 1539 individuals had an incident ADHD medication dispensation 
between 1 January, 2007 and 30 June, 2013. Among these, a total of 127 events occurred in 
158 persons during 24 weeks pre- and post-medication initiation (Table 6.4.1). Overall, result 
showed no evidence for a statistically significant increased risk of seizures during 24 weeks 
prior and or post ADHD medication initiation, as compared to the rate during the same 48 
weeks in the year prior (Figure 6.4.1).  
Figure 6.4.1. Incidence rate (IR) of seizures pre and post ADHD medication initiation 
 
Note: The blue line is the estimated IR per 1000 person-weeks throughout 24 weeks pre- and post 
ADHD medication initiation, presented with 95% CI. The red line indicates baseline IR with 95% CI. 
IRs are estimated with natural cubic splines with knots at -24, -12, -4, 4, 12, and 24 weeks 
 
 
Table 6.4.1. Within-individual incidence rate ratio (IRR) for seizure events in the 24 weeks 
pre- and post ADHD medication initiation among 1539 individuals with a seizure history 
 
 
Time-period (weeks) No of events 
Within-individual 
IRR (95% CI) 
Baseline 141 - 
Pre 24-13 30 0.85 (0.57-1.26) 
Pre 12-5 23 0.98 (0.63-1.52) 
Pre 4-0 13 1.11 (0.63-1.95) 
Post 0-4 9 0.77 (0.39-1.50) 
Post 5-12 16 0.68 (0.41-1.14) 
Post 13-24 36 1.02 (0.71-1.47) 
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Repeated medication analyses 
In the full cohort, a total of 24,337 seizure events occurred in 44,827 individuals during 293,876 
person years of follow-up. Results from the Cox regression analyses are presented in Table 
6.4.2. Overall, results from the population-level analyses showed no statistically significant 
difference in the rate of seizures during ADHD-medicated and non-medicated periods, after 
adjusting for age and sex. In the within-individual analyses, which adjust for all time-constant 
confounders within an individual, ADHD-medication periods were associated with a 
statistically significant decreased rate of seizures. These results did no differ markedly when 
adjusting for concurrent AED medication treatment, across sex, or when stratified based on 
clinical ADHD diagnosis, or by the absence or presence of additional NDDs. 
 Table 6.4.2. Hazard ratios for seizure events during ADHD-medication treatment periods, 
compared with non-treatment periods (2006-2013) 
 Note: Model 1 shows the association between ADHD medication and seizures, adjusted for sex and 
age at start of each observation periods in five age bins (5-10, 11-16, 17-22, 23-30 and 31-45 years). 
Model 2 is further adjusted for concurrent AED medications. Model 3 shows risk estimates in each 
strata of combinations for ADHD and AED medication periods, compared to reference periods (no 
medication). Individuals could contribute data to more than one strata. Model 4 shows the association 
stratified by sex, adjusted for age and concurrent AED medication. Model 5 shows the association 
stratified by ADHD diagnosis, ADHD and no additional NDD, ADHD and additional NDD, adjusted 
for categorical age, sex and concurrent AED medication. 95% CIs are presented parentheses. 
  
Analysis 
N 
individuals  
N seizure 
events 
Population-level 
HR (95%CI) 
Within-individual 
HR (95%CI) 
Model 1 
ADHD meds 44827 24337 0.96 (0.77-1.19) 0.77 (0.62-0.95) 
Model 2     
ADHD meds 44827 24337 0.92 (0.74-1.13) 0.77 (0.62-0.95) 
AED meds 44827 24337 3.04 (2.87-3.22) 0.94 (0.87-1.00) 
Model 3     
ADHD meds=1 |  
AED meds=0 1654 44 0.59 (0.42-0.83) 0.69 (0.41-1.18) 
ADHD meds=0 |  
AED meds=1 26798 20151 3.02(2.85-3.19) 0.93 (0.87 -1.00) 
ADHD meds=1 |  
AED meds=1 1444 432 0.97 (0.78-1.22) 0.78 (0.62-0.96) 
Model 4     
Men only 23332 12225 0.85 (0.63-1.14) 0.80 (0.60-1.06) 
Women only 21495 12112 1.04 (0.78-1.38) 0.73 (0.53-1.01) 
Model 5     
ADHD  3554 2284 0.80 (0.63-1.00) 0.74 (0.59-0.93) 
ADHD + no NDD   1633 761 0.78 (0.55-1.12) 0.61 (0.41-0.91) 
ADHD + additional NDD  1921 1523 0.79 (0.60-1.05) 0.81 (0.61-1.08) 
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7 DISCUSSION AND IMPLICATIONS 
7.1 MAIN FINDINGS   
The main findings from this thesis suggest that ADHD is related to both later maturation and a 
wide range of childhood psychiatric traits, and that these associations are partly due to shared 
genetic risk factors. Further, the shared genetic liability between ADHD and related childhood 
psychiatric traits can in part be attributed to a general liability towards broad childhood 
psychopathology. Comorbidity between ADHD and epilepsy also show moderate genetic 
influence, however individual specific environmental factors contributes more strongly to the 
cross-disorder overlap. ADHD medication does however not appear to be a risk factor for acute 
epileptic seizures among individuals with a seizure history.  
7.1.1 Maturity – one developmentally important aspect of ADHD 
Findings from Study 1 revealed that relative immaturity is significantly associated with higher 
levels of ADHD symptoms, primarily due to shared genetic factors. Nevertheless, the 
magnitude of the association was modest, and diminished with age, with little effect of relative 
immaturity on ADHD symptoms in early adulthood. Majority of the variance in ADHD 
symptoms at all ages was explained by immaturity-independent etiological factors. Results also 
showed evidence for ADHD-related genetic stability across ages, and genetic innovation 
during adolescence and early adulthood. This suggest that immaturity is merely one etiological 
factor contributing to ADHD, and that this effect is largely limited to ADHD symptoms in 
childhood and adolescence.  
Results should be considered within the wider research context. First, it is possible that the 
attenuated genetic and phenotypic association between relative immaturity and ADHD with 
age may be related to the catch up in neurodevelopmental maturation previously reported in 
longitudinal neuroimaging studies of ADHD.5 Together, such findings may partly explain why 
some children show a decrease in ADHD symptoms from childhood to early adulthood. 
Second, although there is clear evidence for a higher risk of clinical ADHD diagnoses among 
children who are born in the last months of the school-year,111-122 our findings suggest that such 
effects may be more strongly related to ADHD in childhood, and less important for ADHD in 
adulthood.112 Nevertheless, comparison across studies are challenging due to differences in 
measures and methodology. Whereas we relied on parent-rated relative immaturity and ADHD 
symptoms, other studies have used birth-month as a proxy for immaturity. There is evidence 
to suggest that the association between birth-month and clinical ADHD is more strongly driven 
by teacher-rated comparison of maturity between children in the classroom, than by parent-
ratings.111  
Increased awareness of the association between maturity and ADHD is important for clinical 
practice and policy. Studies from Denmark, where relatively young children can be held back 
from school start, have not reported an associations between birth-month and ADHD.241,242 
This suggest that flexible school-enrolment may reduce developmentally inappropriate 
demands on children and possibilities for misdiagnosis of ADHD in childhood. For clinicians, 
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the risk of misclassification of ADHD owing to subjective comparisons of immaturity must be 
carefully weighed against findings that immaturity and ADHD in childhood are partly 
explained by common etiologic factors. 
7.1.2 ADHD genetic risk is associated with a liability towards general 
childhood psychopathology  
Findings from Study 2 revealed that ADHD PRS are significantly and positively associated 
with childhood neurodevelopmental, externalizing, and to a lesser extent, internalizing traits. 
Importantly, these associations could largely be accounted for by a general childhood 
psychopathology factor. In addition, about 2/3 of the association between ADHD PRS and 
hyperactivity/impulsivity could attributed to general variance shared across childhood 
psychopathology traits, and about 1/3 to variance specific to hyperactivity/impulsivity. These 
results suggest that common genetic risk variants associated with ADHD, and captured by PRS, 
influence a more general liability towards broad dimensions of childhood psychopathology, in 
addition to specific associations with hyperactivity/impulsivity. 
These findings add to a growing body of research supporting the hypothesis of a genetically 
influenced general psychopathology factor.10,141-144,243 Exciting new work has reported 
significant SNP-h2 for a general psychopathology factor (16%) and associations with reduced 
frontotemporal connectivity, suggesting that dysconnectivity may be a transdiagnostic brain-
based phenotype associated with a genetic liability towards broad childhood 
psychopathology.244 Together, these findings emphasize the utility of adopting a more 
dimensional, multivariate framework, and the need to account for the inter-related nature of 
psychiatric conditions when studying the genetic architecture of childhood psychopathology.10 
Our results add to accumulating quantitative and molecular genetic evidence, showing that 
genetic influences on psychiatric disorder and traits largely transcends current diagnostic 
boundaries, and categorical distinctions between clinical diagnosis and normal variation. 
Whilst taking a dimensional approach to both diagnostics and treatment in psychiatry may be 
premature, it is possible that future revisions of diagnostic systems like the DSM will rely on 
broader dimensions of psychopathology defined by shared etiology.245  
Due to the low predictive power of PRS, identifying shared genetic etiology across psychiatric 
conditions does not yet have any direct clinical implications. Nevertheless, as the power and 
precision of PRS improves, our findings suggest that PRS may become meaningful for 
identifying individuals at risk for psychopathology more broadly, and potentially also for more 
disorder specific screening.246   
7.1.1 Comorbidity between ADHD and epilepsy show moderate genetic 
influence and considerable non-shared environmental influence 
In Study 3, clinically ascertained epilepsy was associated with a 3.5-fold increased risk of 
ADHD (OR=3.5 [95%CI 3.33-3.62]). The risk increase also extended to relatives of individuals 
with epilepsy, and the strength of association across relatives increased along with increased 
genetic relatedness. This suggest that familial co-aggregation between the ADHD and epilepsy 
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is at least in part due to shared genetic risk factors. Evidence from the quantitative genetic 
analyses in full and half-siblings suggested that about 40% (95%CI=9-70) of the phenotypic 
correlation between the liabilities of ADHD and epilepsy could be attributed to genetic factors. 
Nonetheless, the strength of familial aggregation and the estimated genetic correlation between 
ADHD and epilepsy (rg=0.21 [95%CI=0.02-0.40]) was considerably weaker than that 
previously reported between ADHD, ASD and ID.127,128 As these studies were conducted in 
Swedish register-based cohorts, using similar research designs, it is unlikely that this reflects 
methodological differences. Instead, these findings suggest that epilepsy is less genetically 
related to ADHD than traditionally defined DSM-based NDDs, supporting the demarcation 
between neurology and psychopathology. Evidence from a recent study relying on GWAS data 
from over 800,000 individuals support such a conclusion, with limited genetic associations 
observed across neurological and psychiatric disorders, including ADHD and epilepsy.135  
However, an issue for most genetic studies on epilepsy, including the work in this thesis, is the 
necessary trade-off between sufficient sample sizes for statistical inference versus selection of 
a more homogenous phenotype. Considering the marked heterogeneity of epilepsy, current 
research can therefore not rule out a strong genetic link between certain types of epilepsy and 
psychiatric disorders.  
7.1.1.1 If it is not in the genes, then where? 
Nearly 50% of the phenotypic correlation between ADHD and epilepsy could be attributed to 
factors that are not shared by siblings. These findings may indicate direct effects of one disorder 
on the other (i.e. epilepsy causing ADHD, or vice versa) or the importance of non-genetic 
factors that increase the risk for both disorders. Interestingly, we also found slightly stronger 
associations between relative pairs delineated on the maternal side, suggesting that pregnancy 
related factors may be of importance for the cross-disorder association.247,248 Such risk factors 
could contribute to shared familial effects if consistent across pregnancies, or manifest as non-
shared risk if pregnancy specific. Antecedent central nervous system injury, including head 
trauma and neurological insults at birth, may provide a link between the ADHD and 
epilipsy.165,249-251 Personal and maternal history of autoimmune disease have also been linked 
to both disorders respectively,248,252 and a recent molecular study reported significant genetic 
correlations between ADHD and certain autoimmune disorders.253 Finally, de novo mutations 
and CNVs likely contributes to multi-morbidity across epilepsy and neurodevelopmental 
disorder, at least in some cases.148  
Further research is needed to improve understanding of non-genetic risk factors and their role 
in comorbidity across epilepsy, ADHD and other NDDs. For clinicians, evidence of familial 
co-aggregation suggests that ADHD should not merely be regarded as an epiphenomenon of 
epilepsy. Clinical vigilance for other plausible shared risk factors, such as head trauma or 
infections, may be warranted. 
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7.1.2 Pharmacological ADHD treatment is not associated with an 
increased risk of seizures   
Findings from Study 4 showed no evidence for an increased risk of acute seizures associated 
with ADHD medication use among individuals with a history of seizures. Rather, when 
comparing the rate of seizures across ADHD-medicated and non-medicated periods within the 
same individual, estimates showed a statistically significant decreased rate of seizures 
associated with ADHD medication periods. Similar associations were found across sex and 
among individuals with additional NDDs. These finding provide converging evidence with 
several previous studies, using different research designs and measures169,176,179,254,255, showing 
limited support for the hypothesis that ADHD medication in prescribed doses is associated with 
an increased risk of seizures. Unlike most previous studies,179 we relied on a within-individual 
design to adjust for important time-constant confounders that varies between individuals (e.g. 
baseline disorder severity, shared genetic liability) and may influence the association between 
ADHD medication use and seizures. 
Within-individual analyses of seizure rates in the 24 weeks pre- and post ADHD medication 
initiation indicated an overall (non-significant) lower rate of seizures around the time of ADHD 
medication initiation. Although interpretations should be cautious as all CIs included 1, this 
may suggest that starting ADHD medication treatment is more likely in stable seizure periods. 
If so, this could in part explain the reduced rates of seizures observed during ADHD medication 
periods. Alternatively, ADHD medications may improve adherence to AED medications, or 
reduce exposure to factors that can trigger seizures, such as stress and alcohol use. It should be 
noted that we were unable to study seizures which did not require specialist care. As patients 
with epilepsy are less likely to seek medical treatment for minor or typical seizures, we can 
therefore not exclude that ADHD medication may still exacerbate seizures which do not require 
medical attention. 
In conclusion, findings from this study provide no evidence for an overall increased rate of 
seizure events severe enough to warrant medical attention, associated with ADHD medication 
treatment in individuals with a seizure history, without or without NDD multi-morbidity. This 
suggest that seizure history should not automatically preclude patients from receiving ADHD 
medication treatment. 
7.2  METHODOLGICAL CONSIDERATIONS  
7.2.1 Measurement error and misclassification 
7.2.1.1 Parent- and self-rated measures 
Measurements error is a contentious issue in psychopathology assessment for several reasons. 
First, the validity of measurement scales varies. For example, the RI measure used in this thesis 
relied on merely two questions, and has only been evaluated in two studies.187,188 Similarly, the 
A-TAC internalizing scales have not been validated. Although this issues was partly addressed 
using a split a sample approach, showing similar results when using validated internalizing 
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scales (i.e. the SCARED and SMFQ), we cannot firmly assert what these measures capture. 
Secondly, agreement between raters (i.e. parent-, teacher and self-ratings) in psychopathology 
assessment is far from unity. Disagreement between raters may reflect lower measurement 
reliability of type of one rater. Previous research suggests that parent-report is preferential over 
self-report for ADHD256 and ASD257 symptoms, whereas the opposite has been shown for 
anxiety assessments in childhood and adolescence.258 Differences between rater may also 
represent true rater specific variance, highlighting the fact that each rater may experience and 
report unique, yet valid, aspects of behavior.259,260 Finally, rater effects can also indicate rater 
bias, referring to systematic measurement error that is introduced when a rater consistently 
over- or underestimates occurrences of behavior.261 Regardless of the source, measurement 
error can lead to biased estimates of variance and covariance across measured variables. In 
Study 1 and 2, this was in part addressed using SEM to model the latent factors of interest 
separately from rater specific (Study 1) and item specific (Study 2) residuals variance.  
7.2.1.2 Register based ADHD and epilepsy diagnosis 
In Study 3 and 4, ADHD and epilepsy status was ascertained via register data, which may led 
to misclassification of disorder status for several reasons. First, ADHD cases were identified 
from ICD diagnosis given by psychiatric specialists and ADHD medication prescriptions. ICD 
criteria tends captures more severe, combined type ADHD, and until 2016, pharmacotherapy 
was reserved for patients with moderate to severe ADHD. As such, identified ADHD cases 
likely represent more severe cases meaning false negatives cannot be avoided, whereas bias 
due to false positives is less of a concern. Second, the NPR only includes outpatient care from 
2001, possibly leading to misclassification due incomplete coverage. Sensitivity analyses using 
a younger a cohort, with more complete coverage, were run in Study 3 and 4 and suggested 
that results from the main analyses were not substantially biased by differences in the coverage 
of the NPR. 
7.2.1.3 Treatment status by medication 
In Study 4, the definition of ADHD treatment period was based on a sequence of dispensed 
prescriptions that might inaccurately reflect the actual consumption of medication, either due 
to non-adherence, or misspecification of the treatment periods. Although this issue was partly 
addressed via sensitivity analysis using different lengths of time between sequences of 
dispensed prescriptions, we were unable to assess the possibility that patients may discontinue 
treatment immediately after a seizure. This type of exposure time misclassification would lead 
to an underestimation of risk, if the seizure event occurred within 6 months after first 
prescription and no further prescription was filled, as the seizure would then be classified as 
occurring during a non-medicated period. 
7.2.1.4 Seizure events  
In Study 4, seizure events (the outcome) were defined as an unplanned in- or outpatient visit to 
hospital or specialist care for a seizure in the NPR. This relatively broad definition may have 
resulted in the inclusion of visits for ongoing medical management. To partly address this, 
 56 
sensitivity analyses were conducted using a stricter outcome definition. Results from sensitivity 
analyses did not differ markedly from the main results. 
7.2.2 Assumptions in quantitative genetic studies 
The quantitative genetic models used in this thesis rests on several assumptions, some of 
which are outlined in Table 5.2, and some of which are considered below. 
No assortative mating: Twin and extended family designs assumes no strong effects of 
assortative mating.214 The extent to which that assumption holds will vary by trait,262 and recent 
findings have reported evidence of non-random mating within and across psychiatric 
diagnoses, particularly within ADHD and across ADHD and ASD.263 Non-random mating will 
over time lead an underestimation of heritability; given the high heritability found for ADHD 
it seem unlikely that such effects have greatly influenced findings in this thesis. 
Equal environment assumption: The quantitative genetic designs in thesis relied on 
assumption regarding environmental sharing between relatives. The validity of assuming that 
MZ and DZ twins share their environment to a very similar extent has been evaluated and 
confirmed in numerous studies.214 In Study 3, full- and maternal half siblings are assumed to 
share their environment to an equal extent, whilst paternal half siblings are assumed to share 
no environmental effects. Whilst this is clearly a simplification, one Swedish register-based 
sibling study found no significant effect of varying these assumptions, as shared environmental 
factors had a minimal influence on the psychiatric disorders considered in the study, including 
ADHD.142 Considering that there is no strong evidence for the contribution of shared family 
environment to the etiology of ADHD,50,87 this suggest that these assumption may not have 
greatly affected findings in Study 3. 
No gene-gene or gene-environment interaction: Quantitative genetic models assume no 
interaction between A, D, C, and E, and these assumptions were not further evaluated in this 
thesis. Development of efficient methods for assessing gene-environment interplay will be 
important for future research to gain a more complete insight into the etiology of childhood 
psychopathology and neurology. 
7.2.3 Generalizability 
The studies included in this thesis rely on data from nationwide Swedish cohorts with 
prospectively collected information over the past few decades. As such, generalizability to 
countries with similar demographics and access to healthcare is likely to be high. Certain 
findings may also apply to other countries and populations. For example, Study 4 replicates 
findings from a recent large-scale US study,179 despite substantially different health care 
systems and prescription practices for ADHD medication across Sweden and the US. 
Nevertheless, there are other limitations to the generalizability of findings in this thesis. 
First, non-responders in TCHAD and CATSS were more likely to have higher levels of 
psychiatric problems, including ADHD. It is therefore possible that the variation of ADHD and 
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other psychiatric traits considered in Study 1 and 2 are truncated at the extreme, meaning results 
may not be generalize to more severe, clinical cases. Nevertheless, this is only likely to have 
attenuated estimated associations towards the null. Second, we were only able to study seizures 
that led to contact with specialist medical care in Study 4, meaning that findings may not 
generalize to less severe seizures. Third, findings may not generalize to more ethnically diverse 
populations. Families living in ethnically diverse areas were underrepresented in TCHAD (and 
likely also in CATSS). Further, individuals with non-European genetic ancestry were excluded 
from analyses in Study 2. Although methods development are ongoing to accommodate PRS 
analyses of ethnically diverse populations, findings can for now not be automatically 
generalized to non-European populations. Finally, we only included individuals born in 
Sweden to enable linking of family pedigrees in Study 3, meaning results may not generalize 
to residents born outside of Sweden. 
7.2.4 Ethical considerations 
All studies in this thesis were approved by the Regional Ethics Review Board in Stockholm, 
and fall under regulations of the Swedish Ethical Review Act (2003:460), which covers 
research including living and deceased persons, biological material and sensitive information. 
In medical research, researchers must weigh the benefits of the research against the welfare of 
the study participants. Observational studies, like those included this thesis, are generally less 
ethically challenging than experimental studies, as no intervention occurs during data 
collection. In study 1 and 2, all participants gave informed consent. Nonetheless, collection of 
sensitive data regarding children’s health may still cause negative emotions. Study 3 and 4 rely 
on nationwide register-based data. As it stands today, no informed consent is needed in register-
based research and although all register data is anonymized by Statistics Sweden, this may be 
considered a breach of privacy. However, it may also be argued that the use of national registers 
for medical research is of benefit to the Swedish people as it can lead to public health gains and 
provide guidelines for healthcare.204 Beyond issues concerning data safety and consent, clear 
communication of research findings to the general public and affected patient groups is an 
important ethical issue. Findings showing familial risk and genetic liability to childhood 
disorder must be communicated in such a way that blame is not put on the affected families, 
and that it is clear that genetic influences are not deterministic.   
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8 CONCLUSION 
This thesis set out to address two broad questions in relation to ADHD: 1) to investigate the 
role of shared genetic factors for maturation and childhood psychiatric comorbidity in ADHD, 
and 2) to improve understanding of the causes of comorbid ADHD and epilepsy, and treatment 
safety in this patient group. Findings from this thesis expand prior research in several ways.  
First, we show that ADHD is related to parental perceptions of relative immaturity, primarily 
due to shared genetic factors. This association is modest, and limited to childhood and 
adolescence, highlighting that immaturity is merely one aspect contributing to the etiology of 
ADHD across development. Second, common genetic risk variants associated with ADHD, 
and captured by PRS, were found to also influence a wide range of related childhood 
psychiatric traits. Using a relatively novel approach to combine PRS analyses with factor 
analyses, we show that these cross-trait genetic associations may be attributed to a general 
liability towards broad childhood psychopathology. Finally, comorbidity between ADHD and 
epilepsy was found to be only moderately influenced by shared genetic risk factors, and more 
strongly influenced by non-familial risk factors. ADHD medication does however not appear 
to be a risk factor for acute epileptic seizures in individuals with a seizure history, suggesting 
that ADHD medications may be a viable treatment option even in patients with seizures.  
Taken together, results from this thesis highlight important aspects of development and 
comorbidity in ADHD, and lends support to the hypothesis that ADHD may be considered part 
of broader continuum of psychopathology that is underpinned by partly shared genetic liability. 
Based on evidence thus far, this shared genetic liability appears less strongly related to epilepsy.  
8.1 FUTURE DIRECTIONS 
8.1.1 Are all psychiatric disorders the same thing? 
Increasing evidence for a shared genetic liability towards virtually all common 
psychopathology has widespread implications for future research. In general, it suggests that 
the efficiency of future etiological studies may be considerably improved by studying more 
dimensional, multivariate phenotypes. With rapid developments in multi-trait GWAS 
methods,264 future directions is psychiatric genomics will likely include efforts to identify 
genetic variants with pleiotropic effects across disorder, and possibly GWAS focused on broad 
dimensional phenotypes such as the general factor of psychopathology.10,245 Based on recent 
findings linking white matter development and frontotemporal connectivity to broad childhood 
psychopathology dimensions,103,244 it seem likely that most studies aiming to identify 
biological markers of psychiatry will benefit from taking a more trans-diagnostic approach. 
Considering the widespread genetic sharing in psychiatry, can we even expect to find disorder 
specific markers? Although debated,265 evidence from this thesis suggest so. Results from 
Study 2 indicted that about 1/3 of the ADHD PRS association was specific to 
hyperactivity/impulsivity and not shared with general childhood psychopathology. We are 
aware of at least one other study reporting genetic specificity in ADHD by showing that ADHR 
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PRS, but not PRS for other psychiatric conditions, are associated with developmental 
trajectories of ADHD.65 Similarly, results from Study 3 showed only a moderate genetic 
overlap between ADHD and epilepsy. Considered together with previous studies reporting 
limited genetic associations across neurology and psychiatry,135 these findings should stimulate 
research on other non-genetic factors that underpin comorbidity. 
Together, findings from this thesis suggest that by studying what is shared across disorders 
etiologically, we may also gain insight into factors that are disorder specific. Future studies 
aiming to parse disorder-specific genetic factors from genetic factors with more general effects 
across psychopathology will be very important. Although methods development will be needed 
to do so at the level of specific variants, the issue may be partly addressed at the phenotypic 
level. Study 2 in this thesis provides one such example, together with several recent genetic 
and neuroimaging studies.82,103,244  
8.1.2 What causes disorder specificity? 
If genes are largely responsible for influencing a general liability to psychiatry, non-genetic 
factors along the pathway from genotype to phenotype must influence disorder specific 
expression. Yet, most non-genetic and environmental risk factors identified so far for ADHD, 
such as birth complications and childhood SES, do not seem to be disorder specific. To advance 
understanding of causal non-genetic factors in psychiatry, longitudinal epidemiological 
samples with both dense and deep phenotyping will be needed. Further, such data will need to 
be combined with genomic information, or analyzed using genetically informative designs, to 
understand the interplay between genetic and environmental factors across development.245 
Large-scale efforts to study pre- and perinatal, non-genetic and environmental factors in 
consortia settings are making headway,266,267 and many of them include biological data. Yet, 
data harmonization for diverse environmental measures remains a challenge.  As in genetics, 
its seem that studying single disorder exposure-outcome associations may be hampering 
identification of potential risk factors, and that research on environmental  and non-genetic risk 
factors would also benefit from taking a more dimensional and multi-disorder approach. By 
doing so, causes of disorder specificity may also be identified. 
  
 60 
9 ACKNOWLEDGEMENTS 
There are many people to thank for making this PhD journey not only possible, but also some 
of the most exciting and rewarding years of my working life so far.  
Henrik Larsson, my main supervisor. I am so glad that I contacted you during my MSc, and 
that you gave me the chance to come to KI. You are an excellent group leader, researcher, and 
supervisor. Your enthusiasm for research and energy to pull together big research projects, 
whilst also prioritizing a personal life, makes you a great role-model. By encouraging my strong 
sides, and helping me to improve the not so strong ones, you have enabled me to grow both 
personally and as researcher. I could not have hoped for a better supervisor and mentor. 
Ralf Kuja-Halkola, my co-supervisor and statistician in need. I can honestly say that this thesis 
would not have been possible without your help. I know few people who are so generous with 
their knowledge and time, and I have learnt a great dealt about statistics and programming from 
you. When things felt a bit too challenging, your encouragement and support helped me keep 
going. Not the mention all the fun trips, beers shared, and books discussed.  
Benjamin Lahey, my long-distance co-supervisor. Your invaluable expertise and support has 
greatly improved the work included in this thesis, and I have enjoyed working with you.  
Qi Chen and Laura Ghirardi, my office buddies and closest research colleagues. I have learnt 
so much from both of you! Thank you for all the coffees shared, the great travel company, and 
for endless discussions about research and life. I feel truly lucky to have shared my PhD years 
with you. 
Joanna Martin, my coach in psychiatric genetics and post-doc mentor. Meeting in Boulder 
was the start of a great friendship and collaboration, one that I hope will continue. I cannot 
thank you enough for all your support and encouragement over the last two years. 
Paul Lichtenstein, for sharing your sharp eye for research and new ideas with me, and for 
making MEB and the psychiatric epidemiology group such a fantastic place to work. 
To my co-authors, Per-Anders Rydelius, Jan-Olov Larsson, Brian D'Onofrio, Patrick 
Quinn, Kelsey Wiggs, David W. Dunn, Jonna Kuntsi, Catharina Almqvist-Malmros, and 
Søren Dalsgaard. Thank you for your expertise and invaluable contributions to the studies 
involved in this thesis. 
Lu Yi, Robert Karlsson, and Patrick Magnusson, for your amazing work on the CATSS 
genotype data, and your support, without which Study 2 would never have been possible.  
Erik Pettersson, for sharing your expertise on the general factor, and for all your help with 
manuscript and grant writing. I don’t know any other Swede that good at FA or English!  
Zheng Chang, for being such a skilled pharmacoepidemiologist and sharing that expertise with 
me. 
  61 
Nancy Pedersen, for being my mentor and agreeing to host my defense. 
To all the great researcher in the ADHD/Psych epi group, it has been a pleasure to work with 
you! Shihua Sun, Jie Song, Mark Taylor, Alexander Viktorin, Martin Cederlöf, Ylva 
Ginsberg, Charlotte Skoglund, Emma Frans, Sarah Bergen, Amir Sarislan, Gustaf 
Brander, Andrea Johansson Capusan, Lin Li, Anneli Andersson, Ashley Thompson, and 
Tyra Lagerberg. 
Past and present Mebbers for creating a great research environment, (including but not 
limited to) Emilio Ugalde, Tong Gong, Frida Lundström, Elisa Longetti, Hannah Bower, 
Kathleen Bokenberger, Dylan Williams, Miriam Mosing, Miriam Elfström, Ida 
Karlsson, Malin Eriksson, Anna Plym, Elizabeth Dahlqvist, Cheng Xu, Bojing Liu, 
Anne Örtqvist, Vilhelmina Ullemar, Johanna Holm, Gabriel Isheden, Anna Kähler, 
Camilla Sjörs, Nelson Ndegwa, Fang Fang, Sara Hägg, Camilla Ahlqvist, Gunilla 
Sonnebring, Gunilla Nilsson Roos and many more! 
A special thanks to Shuyang Yao, for sharing this PhD journey and your amazingly generous 
personality, Vide Ohlsson Gotby, for being a good listener and fun friend, both at and outside 
research, Mina Rydell, for your support and advice along the way, Andreas Jangmo, for all 
the laughs and your help with stats, and Camilla Wiklund, for being a great office mate the 
last few months. 
Carolyn Cesta, my sister in science and crime. Thanks for the great work in the PhD group, 
your help with the kappa, and for listening to me obsess about this thesis for the last months. 
Your independence and confidence in research and life continually inspires me. 
Andrea Foebel, Bronwyn Haasdyk Brew, and Kelli Lehto, for your friendship and for 
being fantastic role-models. With women like you in science and policy, I can hear the glass 
ceiling cracking. 
Moritz, Emily, and Fatima, for all those days and nights in the Goldsmiths library. I 
wouldn’t be here without them. 
Marie, Moa, Lone, Linda and Ziggy, for filling my life with friendship, and ensuring that 
there is more to life than work.  
Nicklas, for all the good times we had and for showing me that anything is possible if you are 
just crazy enough to pursue it. You will be forever missed. 
My brothers John and Albert, and especially my mother Margareta and father Anders, for 
always supporting me, teaching me the value of solidarity with your ‘medmänniska’, and for 
providing a strong foundation for me to start from. 
Henrik, for endlessly cheering me on through eight years of studies and research, for 
supporting my career choices, but mostly for being you. You make my life fun and filled with 
love. 
 62 
10 REFERENCES 
1. Thapar, A. & Cooper, M. Attention deficit hyperactivity disorder. Lancet (2015). 
2. Biederman, J. et al. Predictors of persistence and remission of ADHD into adolescence: 
results from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 35, 
343-51 (1996). 
3. Cheung, C.H. et al. Childhood predictors of adolescent and young adult outcome in ADHD. J 
Psychiatr Res 62, 92-100 (2015). 
4. Faraone, S., Biederman, J. & Mick, E. The age-dependent decline of attention deficit 
hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 36, 159 - 165 
(2006). 
5. Shaw, P. et al. Trajectories of cerebral cortical development in childhood and adolescence and 
adult attention-deficit/hyperactivity disorder. Biol Psychiatry 74, 599-606 (2013). 
6. Larsson, J., Larsson, H. & Lichtenstein, P. Genetic and environmental contributions to 
stability and change of ADHD symptoms between 8 and 13 years of age: a longitudinal twin 
study. Journal of the American Academy of Child and Adolescent Psychiatry 43, 1267 - 1275 
(2004). 
7. Pingault, J., Viding, E., Galéra, C. & et al. Genetic and environmental influences on the 
developmental course of attention-deficit/hyperactivity disorder symptoms from childhood to 
adolescence. JAMA Psychiatry 72, 651-658 (2015). 
8. Jensen, C.M. & Steinhausen, H.-C. Comorbid mental disorders in children and adolescents 
with attention-deficit/hyperactivity disorder in a large nationwide study. ADHD Attention 
Deficit and Hyperactivity Disorders 7, 27-38 (2015). 
9. Martin, J., Taylor, M.J. & Lichtenstein, P. Assessing the evidence for shared genetic risks 
across psychiatric disorders and traits. Psychological Medicine, 1-16 (2017). 
10. Lahey, B.B., Krueger, R.F., Rathouz, P.J., Waldman, I.D. & Zald, D.H. A hierarchical causal 
taxonomy of psychopathology across the life span. Psychol Bull 143, 142-186 (2017). 
11. Davis, S.M. et al. Epilepsy in children with attention-deficit/hyperactivity disorder. Pediatr 
Neurol 42, 325-30 (2010). 
12. Socanski, D., Aurlien, D., Herigstad, A., Thomsen, P.H. & Larsen, T.K. Epilepsy in a large 
cohort of children diagnosed with attention deficit/hyperactivity disorders (ADHD). Seizure 
22, 651-5 (2013). 
13. Russ, S.A., Larson, K. & Halfon, N. A national profile of childhood epilepsy and seizure 
disorder. Pediatrics 129, 256-64 (2012). 
14. Bertelsen, E.N., Larsen, J.T., Petersen, L., Christensen, J. & Dalsgaard, S. Childhood 
Epilepsy, Febrile Seizures, and Subsequent Risk of ADHD. Pediatrics 138(2016). 
15. Hamoda, H.M., Guild, D.J., Gumlak, S., Travers, B.H. & Gonzalez-Heydrich, J. Association 
between attention-deficit/hyperactivity disorder and epilepsy in pediatric populations. Expert 
Rev Neurother 9, 1747-54 (2009). 
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 
(Washington, DC, 2013). 
17. Scassellati, C., Bonvicini, C., Faraone, S.V. & Gennarelli, M. Biomarkers and attention-
deficit/hyperactivity disorder: a systematic review and meta-analyses. J Am Acad Child 
Adolesc Psychiatry 51, 1003-1019.e20 (2012). 
18. World Health Organization. The ICD-10 classification of mental and behavioural disorders: 
clinical descriptions and diagnostic guidelines, (World Health Organization, 1992). 
  63 
19. Polanczyk, G.V., Salum, G.A., Sugaya, L.S., Caye, A. & Rohde, L.A. Annual research 
review: A meta-analysis of the worldwide prevalence of mental disorders in children and 
adolescents. J Child Psychol Psychiatry 56, 345-65 (2015). 
20. Thomas, R., Sanders, S., Doust, J., Beller, E. & Glasziou, P. Prevalence of attention-
deficit/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics 135, e994-
1001 (2015). 
21. Polanczyk, G.V., Willcutt, E.G., Salum, G.A., Kieling, C. & Rohde, L.A. ADHD prevalence 
estimates across three decades: an updated systematic review and meta-regression analysis. 
International Journal of Epidemiology (2014). 
22. Simon, V., Czobor, P., Balint, S., Meszaros, A. & Bitter, I. Prevalence and correlates of adult 
attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry 194, 204-11 (2009). 
23. Faraone, S.V., Sergeant, J., Gillberg, C. & Biederman, J. The worldwide prevalence of 
ADHD: is it an American condition? World Psychiatry 2, 104-13 (2003). 
24. Rydell, M., Lundstrom, S., Gillberg, C., Lichtenstein, P. & Larsson, H. Has the attention 
deficit hyperactivity disorder phenotype become more common in children between 2004 and 
2014? Trends over 10 years from a Swedish general population sample. J Child Psychol 
Psychiatry (2018). 
25. Liang, J., Matheson, B.E. & Douglas, J.M. Mental Health Diagnostic Considerations in 
Racial/Ethnic Minority Youth. J Child Fam Stud 25, 1926-40 (2016). 
26. Sciutto, M. & Eisenberg, M. Evaluating the evidence for and against the overdiagnosis of 
ADHD. J Atten Disord 11, 106 - 113 (2007). 
27. Ginsberg, Y., Quintero, J., Anand, E., Casillas, M. & Upadhyaya, H.P. Underdiagnosis of 
attention-deficit/hyperactivity disorder in adult patients: a review of the literature. Prim Care 
Companion CNS Disord 16(2014). 
28. Hinshaw, S.P., Owens, E.B., Sami, N. & Fargeon, S. Prospective follow-up of girls with 
attention-deficit/hyperactivity disorder into adolescence: Evidence for continuing cross-
domain impairment. J Consult Clin Psychol 74, 489-499 (2006). 
29. Kuehn, B.M. Women’s use of adhd drugs skyrockets. JAMA 319, 762-762 (2018). 
30. Polanczyk, G., de Lima, M.S., Horta, B.L., Biederman, J. & Rohde, L.A. The worldwide 
prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 
164(2007). 
31. Caye, A., Rocha, T., Anselmi, L. & et al. Attention-deficit/hyperactivity disorder trajectories 
from childhood to young adulthood: Evidence from a birth cohort supporting a late-onset 
syndrome. JAMA Psychiatry 73, 705-712 (2016). 
32. Martin, J. et al. A Genetic Investigation of Sex Bias in the Prevalence of Attention-
Deficit/Hyperactivity Disorder. Biological Psychiatry. 
33. Läkemedelsverket. Läkemedel vid adhd - behandlingsrekommendation: Information från 
Läkemedelsverket. 27(2):13–23.(2016). 
34. Fredriksen, M., Halmoy, A., Faraone, S.V. & Haavik, J. Long-term efficacy and safety of 
treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and 
naturalistic studies. Eur Neuropsychopharmacol 23, 508-27 (2013). 
35. Cortese, S. et al. Practitioner Review: Current best practice in the management of adverse 
events during treatment with ADHD medications in children and adolescents. Journal of 
Child Psychology and Psychiatry 54, 227-246 (2013). 
36. Lichtenstein , P. et al. Medication for Attention Deficit–Hyperactivity Disorder and 
Criminality. New England Journal of Medicine 367, 2006-2014 (2012). 
 64 
37. Dalsgaard, S., Leckman, J.F., Mortensen, P.B., Nielsen, H.S. & Simonsen, M. Effect of drugs 
on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective 
cohort study. The Lancet Psychiatry 2, 702-709 (2015). 
38. Chang, Z., Quinn, P.D., Hur, K. & et al. Association between medication use for attention-
deficit/hyperactivity disorder and risk of motor vehicle crashes. JAMA Psychiatry 74, 597-603 
(2017). 
39. Chen, Q. et al. Drug treatment for attention-deficit/hyperactivity disorder and suicidal 
behaviour: register based study. BMJ : British Medical Journal 348(2014). 
40. Man, K.K.C. et al. Association of Risk of Suicide Attempts With Methylphenidate Treatment. 
JAMA Psychiatry 74, 1048-1055 (2017). 
41. Lu, Y., Sjölander, A., Cederlöf, M. & et al. Association between medication use and 
performance on higher education entrance tests in individuals with attention-
deficit/hyperactivity disorder. JAMA Psychiatry 74, 815-822 (2017). 
42. Chang, Z., D'Onofrio, B.M., Quinn, P.D., Lichtenstein, P. & Larsson, H. Medication for 
Attention-Deficit/Hyperactivity Disorder and Risk for Depression: A Nationwide 
Longitudinal Cohort Study. Biol Psychiatry 80, 916-922 (2016). 
43. Quinn, P.D. et al. ADHD medication and substance-related problems. American journal of 
psychiatry 174, 877-885 (2017). 
44. Graham, J. et al. European guidelines on managing adverse effects of medication for ADHD. 
Eur Child Adolesc Psychiatry 20, 17-37 (2011). 
45. Kanner, A.M. Management of psychiatric and neurological comorbidities in epilepsy. Nature 
Reviews Neurology 12, 106 (2016). 
46. Bachmann, C.J. et al. Trends in ADHD medication use in children and adolescents in five 
western countries, 2005-2012. Eur Neuropsychopharmacol 27, 484-493 (2017). 
47. Man, K.K.C. et al. ADHD Drug Prescribing Trend Is Increasing Among Children and 
Adolescents in Hong Kong. J Atten Disord 21, 1161-1168 (2017). 
48. Furu, K. et al. Utilization of Stimulants and Atomoxetine for Attention-Deficit/Hyperactivity 
Disorder among 5.4 Million Children Using Population-Based Longitudinal Data. Basic & 
Clinical Pharmacology & Toxicology 120, 373-379 (2017). 
49. Norum, J., Olsen, A.I., Nohr, F.I., Heyd, A. & Totth, A. Medical treatment of children and 
youths with attention-deficit/hyperactivity disorder (ADHD): a Norwegian Prescription 
Registry Based Study. Glob J Health Sci 6, 155-62 (2014). 
50. Nikolas, M.A. & Burt, S.A. Genetic and environmental influences on ADHD symptom 
dimensions of inattention and hyperactivity: a meta-analysis. J Abnorm Psychol 119, 1-17 
(2010). 
51. Brikell, I., Kuja-Halkola, R. & Larsson, H. Heritability of attention-deficit hyperactivity 
disorder in adults. Am J Med Genet B Neuropsychiatr Genet 168, 406-413 (2015). 
52. Thapar, A. et al. Psychiatric gene discoveries shape evidence on ADHD's biology. Mol 
Psychiatry (2015). 
53. Larsson, H., Lichtenstein, P. & Larsson, J.O. Genetic contributions to the development of 
ADHD subtypes from childhood to adolescence. J Am Acad Child Adolesc Psychiatry 45, 
973-81 (2006). 
54. Greven, C., Asherson, P., Rijsdijk, F. & Plomin, R. A Longitudinal Twin Study on the 
Association Between Inattentive and Hyperactive-Impulsive ADHD Symptoms. Journal of 
Abnormal Child Psychology 39, 623-632 (2011). 
  65 
55. Greven, C.U., Rijsdijk, F.V. & Plomin, R. A twin study of ADHD symptoms in early 
adolescence: hyperactivity-impulsivity and inattentiveness show substantial genetic overlap 
but also genetic specificity. J Abnorm Child Psychol 39, 265-75 (2011). 
56. Larsson, H., Anckarsater, H., Rastam, M., Chang, Z. & Lichtenstein, P. Childhood attention-
deficit hyperactivity disorder as an extreme of a continuous trait: a quantitative genetic study 
of 8,500 twin pairs. J Child Psychol Psychiatry 53, 73-80 (2012). 
57. Levy, F., Hay, D., McStephen, M., Wood, C. & Waldman, I. Attention-deficit hyperactivity 
disorder: a category or a continuum? Genetic analysis of a large-scale twin study. J Am Acad 
Child Adolesc Psychiatry 36, 737 - 744 (1997). 
58. Taylor, M.J. et al. Genetic evidence for shared risks across psychiatric disorders and related 
traits in a Swedish population twin sample. bioRxiv (2017). 
59. Demontis, D. et al. Discovery Of The First Genome-Wide Significant Risk Loci For ADHD. 
bioRxiv (2017). 
60. Middeldorp, C.M. et al. A Genome-Wide Association Meta-Analysis of Attention-
Deficit/Hyperactivity Disorder Symptoms in Population-Based Pediatric Cohorts. J Am Acad 
Child Adolesc Psychiatry 55, 896-905.e6 (2016). 
61. Satterstrom, F.K. et al. ASD and ADHD have a similar burden of rare protein-truncating 
variants. bioRxiv (2018). 
62. Martin, J., O'Donovan, M.C., Thapar, A., Langley, K. & Williams, N. The relative 
contribution of common and rare genetic variants to ADHD. Transl Psychiatry 5, e506 
(2015). 
63. Martin, J. et al. Copy number variation and neurodevelopmental problems in females and 
males in the general population. bioRxiv (2017). 
64. Martin, J., Hamshere, M.L., Stergiakouli, E., O’Donovan, M.C. & Thapar, A. Genetic risk for 
attention-deficit/hyperactivity disorder contributes to neurodevelopmental traits in the general 
population. Biol Psychiatry 76(2014). 
65. Riglin, L., Collishaw, S., Thapar, A.K. & et al. Association of genetic risk variants with 
attention-deficit/hyperactivity disorder trajectories in the general population. JAMA 
Psychiatry 73, 1285-1292 (2016). 
66. Groen-Blokhuis, M.M. et al. Attention-Deficit/Hyperactivity Disorder Polygenic Risk Scores 
Predict Attention Problems in a Population-Based Sample of Children. Journal of the 
American Academy of Child & Adolescent Psychiatry 53, 1123-1129.e6 (2014). 
67. Brikell, I. et al. The contribution of common genetic risk variants for ADHD to a general 
factor of childhood psychopathology. bioRxiv (2017). 
68. Stergiakouli, E. et al. Shared genetic influences between attention-deficit/hyperactivity 
disorder (ADHD) traits in children and clinical ADHD. J Am Acad Child Adolesc Psychiatry 
54, 322-7 (2015). 
69. Chen, Q. et al. Familial aggregation of attention-deficit/hyperactivity disorder. J Child 
Psychol Psychiatry 58, 231-239 (2017). 
70. Greven, C.U., Harlaar, N., Dale, P.S. & Plomin, R. Genetic Overlap between ADHD 
Symptoms and Reading is largely Driven by Inattentiveness rather than Hyperactivity-
Impulsivity. J Can Acad Child Adolesc Psychiatry 20, 6-14 (2011). 
71. Greven, C.U., Kovas, Y., Willcutt, E.G., Petrill, S.A. & Plomin, R. Evidence for shared 
genetic risk between ADHD symptoms and reduced mathematics ability: a twin study. J 
Child Psychol Psychiatry 55, 39-48 (2014). 
 66 
72. Wadsworth, S.J., DeFries, J.C., Willcutt, E.G., Pennington, B.F. & Olson, R.K. The Colorado 
longitudinal twin study of reading difficulties and ADHD: Etiologies of comorbidity and 
stability. Twin Research and Human Genetics 18, 755-761 (2015). 
73. Dick, D.M., Viken, R.J., Kaprio, J., Pulkkinen, L. & Rose, R.J. Understanding the 
Covariation Among Childhood Externalizing Symptoms: Genetic and Environmental 
Influences on Conduct Disorder, Attention Deficit Hyperactivity Disorder, and Oppositional 
Defiant Disorder Symptoms. Journal of Abnormal Child Psychology 33, 219-229 (2005). 
74. Tuvblad, C., Zheng, M., Raine, A. & Baker, L.A. A common genetic factor explains the 
covariation among ADHD ODD and CD symptoms in 9–10 year old boys and girls. Journal 
of abnormal child psychology 37, 153-167 (2009). 
75. Kuja-Halkola, R., Lichtenstein, P., D'Onofrio, B.M. & Larsson, H. Codevelopment of ADHD 
and externalizing behavior from childhood to adulthood. J Child Psychol Psychiatry (2014). 
76. Nadder, T.S., Rutter, M., Silberg, J., Maes, H. & Eaves, L. Genetic effects on the variation 
and covariation of attention deficit-hyperactivity disorder (ADHD) and oppositional-defiant 
disorder/conduct disorder (ODD/CD) symptomatologies across informant and occasion of 
measurement. Psychological medicine 32, 39-53 (2002). 
77. Stergiakouli, E. et al. Shared genetic influences between dimensional ASD and ADHD 
symptoms during child and adolescent development. Molecular Autism 8, 18 (2017). 
78. Grove, J. et al. Common risk variants identified in autism spectrum disorder. bioRxiv (2017). 
79. Stergiakouli, E. et al. Association between polygenic risk scores for attention-deficit 
hyperactivity disorder and educational and cognitive outcomes in the general population. Int J 
Epidemiol (2016). 
80. Martin, J., Hamshere, M.L., Stergiakouli, E., O'Donovan, M.C. & Thapar, A. Neurocognitive 
abilities in the general population and composite genetic risk scores for attention-deficit 
hyperactivity disorder. J Child Psychol Psychiatry 56, 648-56 (2015). 
81. Du Rietz, E. et al. Association of Polygenic Risk for Attention-Deficit/Hyperactivity Disorder 
With Co-occurring Traits and Disorders. Biological Psychiatry: Cognitive Neuroscience and 
Neuroimaging (2017). 
82. Verhoef, E. et al. Disentangling genetic overlap between Attention-Deficit/Hyperactivity 
Disorder, literacy and language. bioRxiv (2018). 
83. Hamshere, M.L. et al. High loading of polygenic risk for ADHD in children with comorbid 
aggression. Am J Psychiatry 170, 909-16 (2013). 
84. Skoglund, C., Chen, Q., D′Onofrio, B.M., Lichtenstein, P. & Larsson, H. Familial 
confounding of the association between maternal smoking during pregnancy and ADHD in 
offspring. Journal of Child Psychology and Psychiatry 55, 61-68 (2014). 
85. Langley, K., Heron, J., Smith, G.D. & Thapar, A. Maternal and paternal smoking during 
pregnancy and risk of ADHD symptoms in offspring: testing for intrauterine effects. Am J 
Epidemiol 176, 261-8 (2012). 
86. Thapar, A. et al. Prenatal smoking might not cause attention-deficit/hyperactivity disorder: 
evidence from a novel design. Biol Psychiatry 66, 722-7 (2009). 
87. Burt, S.A. Rethinking environmental contributions to child and adolescent psychopathology: 
a meta-analysis of shared environmental influences. Psychol Bull 135, 608-37 (2009). 
88. Plomin, R., DeFries, J.C., Knopik, V.S. & Neiderhiser, J.M. Top 10 Replicated Findings from 
Behavioral Genetics. Perspectives on psychological science : a journal of the Association for 
Psychological Science 11, 3-23 (2016). 
  67 
89. Thapar, A., Cooper, M., Eyre, O. & Langley, K. What have we learnt about the causes of 
ADHD? J Child Psychol Psychiatry 54, 3-16 (2013). 
90. Thapar, A. et al. Prenatal smoking might not cause attention-deficit/hyperactivity disorder: 
evidence from a novel design. Biol Psychiatry 66, 722 - 727 (2009). 
91. D'Onofrio, B.M. et al. Paternal age at childbearing and offspring psychiatric and academic 
morbidity. JAMA Psychiatry 71, 432-8 (2014). 
92. Larsson, H., Sariaslan, A., Långström, N., D'Onofrio, B. & Lichtenstein, P. Family income in 
early childhood and subsequent attention deficit/hyperactivity disorder: a quasi-experimental 
study. Journal of Child Psychology and Psychiatry 55, 428-435 (2014). 
93. Hultman, C.M. et al. Birth weight and attention-deficit/hyperactivity symptoms in childhood 
and early adolescence: a prospective Swedish twin study. J Am Acad Child Adolesc 
Psychiatry 46, 370-7 (2007). 
94. Stevens, S.E. et al. Inattention/overactivity following early severe institutional deprivation: 
presentation and associations in early adolescence. J Abnorm Child Psychol 36, 385-98 
(2008). 
95. Fluegge, K. Does environmental exposure to the greenhouse gas, N2O, contribute to 
etiological factors in neurodevelopmental disorders? A mini-review of the evidence. 
Environmental Toxicology and Pharmacology 47, 6-18 (2016). 
96. Ystrom, E. et al. Prenatal Exposure to Acetaminophen and Risk of ADHD. Pediatrics 
140(2017). 
97. Brandlistuen, R.E., Ystrom, E., Nulman, I., Koren, G. & Nordeng, H. Prenatal paracetamol 
exposure and child neurodevelopment: a sibling-controlled cohort study. International 
Journal of Epidemiology 42, 1702-1713 (2013). 
98. Diagnostic and Statistical Manual of Mental Disorders, (American Psychiatric Association, 
Arlington, VA, 2000). 
99. Man, K.K.C. et al. Prenatal antidepressant exposure and the risk of attention-deficit 
hyperactivity disorder in children: A systematic review and meta-analysis. Neuroscience & 
Biobehavioral Reviews 86, 1-11 (2018). 
100. Shaw, M. et al. A systematic review and analysis of long-term outcomes in attention deficit 
hyperactivity disorder: effects of treatment and non-treatment. BMC Medicine 10, 99 (2012). 
101. Klein, R.G. et al. Clinical and functional outcome of childhood attention-deficit/hyperactivity 
disorder 33 years later. Arch Gen Psychiatry 69, 1295-303 (2012). 
102. Dalsgaard, S., Østergaard, S.D., Leckman, J.F., Mortensen, P.B. & Pedersen, M.G. Mortality 
in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide 
cohort study. The Lancet 385, 2190-2196 (2015). 
103. Muetzel, R.L. et al. Tracking Brain Development and Dimensional Psychiatric Symptoms in 
Children: A Longitudinal Population-Based Neuroimaging Study. Am J Psychiatry 175, 54-
62 (2018). 
104. Biederman, J. et al. High risk for attention deficit hyperactivity disorder among children of 
parents with childhood onset of the disorder: a pilot study. The Am J Psychiatry 152, 431 - 
435 (1995). 
105. Franke, B. et al. The genetics of attention deficit/hyperactivity disorder in adults, a review. 
Mol Psychiatry 17, 960-87 (2012). 
106. Chang, Z., Lichtenstein, P., Asherson, P.J. & Larsson, H. Developmental twin study of 
attention problems: high heritabilities throughout development. JAMA Psychiatry 70, 311-8 
(2013). 
 68 
107. Kan, K.J. et al. Genetic and environmental stability in attention problems across the lifespan: 
evidence from the Netherlands twin register. J Am Acad Child Adolesc Psychiatry 52, 12-25 
(2013). 
108. Shaw, P. et al. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical 
maturation. Proc Natl Acad Sci U S A 104, 19649-54 (2007). 
109. Shaw, P. et al. Cortical development in typically developing children with symptoms of 
hyperactivity and impulsivity: support for a dimensional view of attention deficit 
hyperactivity disorder. Am J Psychiatry 168, 143-51 (2011). 
110. Mous, S.E. et al. Cortical thickness and inattention/hyperactivity symptoms in young 
children: a population-based study. Psychol Med 44, 3203-13 (2014). 
111. Elder, T.E. The importance of relative standards in ADHD diagnoses: evidence based on 
exact birth dates. J Health Econ 29, 641-56 (2010). 
112. Halldner, L. et al. Relative immaturity and ADHD: findings from nationwide registers, 
parent- and self-reports. J Child Psychol Psychiatry 55, 897-904 (2014). 
113. Morrow, R.L. et al. Influence of relative age on diagnosis and treatment of attention-
deficit/hyperactivity disorder in children. Cmaj 184, 755-62 (2012). 
114. Zoega, H., Valdimarsdottir, U.A. & Hernandez-Diaz, S. Age, academic performance, and 
stimulant prescribing for ADHD: a nationwide cohort study. Pediatrics 130, 1012-8 (2012). 
115. Evans, W.N., Morrill, M.S. & Parente, S.T. Measuring inappropriate medical diagnosis and 
treatment in survey data: The case of ADHD among school-age children. J Health Econ 29, 
657-73 (2010). 
116. Krabbe, E.E., Thoutenhoofd, E.D., Conradi, M., Pijl, S.J. & Batstra, L. Birth month as 
predictor of ADHD medication use in Dutch school classes. European Journal of Special 
Needs Education 29, 571-578 (2014). 
117. Librero, J., Izquierdo-María, R., García-Gil, M. & Peiró, S. Edad relativa de los niños en clase 
y tratamiento farmacológico del trastorno por déficit de atención/hiperactividad. Estudio 
poblacional en un departamento de salud. Medicina Clínica 145, 471-476 (2015). 
118. Hoshen, M.B., Benis, A., Keyes, K.M. & Zoëga, H. Stimulant use for ADHD and relative age 
in class among children in Israel. Pharmacoepidemiology and Drug Safety 25, 652-660 
(2016). 
119. Chen, M.-H. et al. Influence of Relative Age on Diagnosis and Treatment of Attention-Deficit 
Hyperactivity Disorder in Taiwanese Children. The Journal of Pediatrics 172, 162-167.e1 
(2016). 
120. Schwandt, H. & Wuppermann, A. The youngest get the pill: ADHD misdiagnosis in 
Germany, its regional correlates and international comparison. Labour Economics 43, 72-86 
(2016). 
121. Whitely, M., Phillimore, J., Lester, L. & Robinson, S. Influence of birth month on the 
probability of Western Australian children being treated for ADHD. Med J Aust 207, 268-269 
(2017). 
122. Karlstad, O., Furu, K., Stoltenberg, C., Haberg, S.E. & Bakken, I.J. ADHD treatment and 
diagnosis in relation to children's birth month: Nationwide cohort study from Norway. Scand 
J Public Health 45, 343-349 (2017). 
123. Biederman, J., Petty, C.R., Clarke, A., Lomedico, A. & Faraone, S.V. Predictors of persistent 
ADHD: an 11-year follow-up study. J Psychiatr Res 45, 150-5 (2011). 
  69 
124. Lichtenstein, P., Carlstrom, E., Rastam, M., Gillberg, C. & Anckarsater, H. The genetics of 
autism spectrum disorders and related neuropsychiatric disorders in childhood. Am J 
Psychiatry 167, 1357-63 (2010). 
125. Tung, I. et al. Patterns of Comorbidity Among Girls With ADHD: A Meta-analysis. 
Pediatrics 138(2016). 
126. Aaberg, K.M. et al. Comorbidity and Childhood Epilepsy: A Nationwide Registry Study. 
Pediatrics 138(2016). 
127. Ghirardi, L. et al. The familial co-aggregation of ASD and ADHD: a register-based cohort 
study. Mol Psychiatry (2017). 
128. Faraone, S.V., Ghirardi, L., Kuja-Halkola, R., Lichtenstein, P. & Larsson, H. The Familial 
Co-Aggregation of Attention-Deficit/Hyperactivity Disorder and Intellectual Disability: A 
Register-Based Family Study. J Am Acad Child Adolesc Psychiatry 56, 167-174.e1 (2017). 
129. Nadder, T.S., Rutter, M., Silberg, J.L., Maes, H.H. & Eaves, L.J. Genetic effects on the 
variation and covariation of attention deficit-hyperactivity disorder (ADHD) and 
oppositional-defiant disorder/conduct disorder (Odd/CD) symptomatologies across informant 
and occasion of measurement. Psychol Med 32, 39-53 (2002). 
130. Faraone, S.V. & Biederman, J. Do attention deficit hyperactivity disorder and major 
depression share familial risk factors? Journal of Nervous and Mental Disease 185, 533-541 
(1997). 
131. Faraone, S.V. & Biederman, J. Depression: a family affair. Lancet 351, 158 (1998). 
132. Segenreich, D. et al. Multilevel analysis of ADHD, anxiety and depression symptoms 
aggregation in families. Eur Child Adolesc Psychiatry 24, 525-36 (2015). 
133. Spatola, C.A. et al. A general population twin study of the CBCL/6-18 DSM-oriented scales. 
J Am Acad Child Adolesc Psychiatry 46, 619-27 (2007). 
134. Bulik-Sullivan, B. et al. An Atlas of Genetic Correlations across Human Diseases and Traits, 
(2015). 
135. Anttila, V. et al. Analysis of shared heritability in common disorders of the brain. bioRxiv 
(2016). 
136. Krapohl, E. et al. Phenome-wide analysis of genome-wide polygenic scores. Mol Psychiatry 
21, 1188-1193 (2016). 
137. Cross-Disorder Group of the Psychiatric Genomics, C. Identification of risk loci with shared 
effects on five major psychiatric disorders: a genome-wide analysis. The Lancet 381, 1371-
1379 (2013). 
138. Jansen, P.R. et al. Polygenic scores for schizophrenia and educational attainment are 
associated with behavioural problems in early childhood in the general population. Journal of 
Child Psychology and Psychiatry 59, 39-47 (2018). 
139. Lahey, B.B., Van Hulle, C.A., Singh, A.L., Waldman, I.D. & Rathouz, P.J. Higher-order 
genetic and environmental structure of prevalent forms of child and adolescent 
psychopathology. Archives of General Psychiatry 68, 181-189 (2011). 
140. Caspi, A. et al. The p Factor: One General Psychopathology Factor in the Structure of 
Psychiatric Disorders? Clinical psychological science : a journal of the Association for 
Psychological Science 2, 119-137 (2014). 
141. Pettersson, E., Anckarsater, H., Gillberg, C. & Lichtenstein, P. Different neurodevelopmental 
symptoms have a common genetic etiology. J Child Psychol Psychiatry 54, 1356-65 (2013). 
 70 
142. Pettersson, E., Larsson, H. & Lichtenstein, P. Common psychiatric disorders share the same 
genetic origin: a multivariate sibling study of the Swedish population. Mol Psychiatry 21, 
717-721 (2016). 
143. Waldman, I.D., Poore, H.E., van Hulle, C., Rathouz, P.J. & Lahey, B.B. External validity of a 
hierarchical dimensional model of child and adolescent psychopathology: Tests using 
confirmatory factor analyses and multivariate behavior genetic analyses. J Abnorm Psychol 
125, 1053-1066 (2016). 
144. Pappa, I. et al. Single Nucleotide Polymorphism Heritability of Behavior Problems in 
Childhood: Genome-Wide Complex Trait Analysis. J Am Acad Child Adolesc Psychiatry 54, 
737-44 (2015). 
145. Neumann, A. et al. Single Nucleotide Polymorphism Heritability of a General 
Psychopathology Factor in Children. J Am Acad Child Adolesc Psychiatry 55, 1038-1045 e4 
(2016). 
146. Brikell, I. et al. Familial liability to Epilepsy and ADHD: A Nationwide Cohort Study. 
Biological Psychiatry (2017). 
147. Chou, I.C. et al. Correlation between epilepsy and attention deficit hyperactivity disorder: a 
population-based cohort study. PLoS One 8, e57926 (2013). 
148. Moreno-De-Luca, A. et al. Developmental brain dysfunction: revival and expansion of old 
concepts based on new genetic evidence. The Lancet Neurology 12, 406-414 (2013). 
149. Singh, A. & Trevick, S. The Epidemiology of Global Epilepsy. Neurol Clin 34, 837-847 
(2016). 
150. Fisher, R.S. et al. ILAE Official Report: A practical clinical definition of epilepsy. Epilepsia 
55, 475-482 (2014). 
151. Fisher, R.S. et al. Operational classification of seizure types by the International League 
Against Epilepsy: Position Paper of the ILAE Commission for Classification and 
Terminology. Epilepsia 58, 522-530 (2017). 
152. Scheffer, I.E. et al. ILAE classification of the epilepsies: Position paper of the ILAE 
Commission for Classification and Terminology. Epilepsia 58, 512-521 (2017). 
153. Jette, N. et al. ICD coding for epilepsy: past, present, and future--a report by the International 
League Against Epilepsy Task Force on ICD codes in epilepsy. Epilepsia 56, 348-55 (2015). 
154. Christensen, J., Vestergaard, M., Olsen, J. & Sidenius, P. Validation of epilepsy diagnoses in 
the Danish National Hospital Register. Epilepsy Research 75, 162-170 (2007). 
155. Banerjee, P.N., Filippi, D. & Allen Hauser, W. The descriptive epidemiology of epilepsy-a 
review. Epilepsy Res 85, 31-45 (2009). 
156. Hauser, W.A. Epidemiology of epilepsy in children. Pellock's Pediatric Epilepsy: Diagnosis 
and Therapy, 177 (2016). 
157. Forsgren, L., Beghi, E., Õun, A. & Sillanpää, M. The epidemiology of epilepsy in Europe – a 
systematic review. European Journal of Neurology 12, 245-253 (2005). 
158. Peljto, A.L. et al. Familial risk of epilepsy: a population-based study. Brain 137, 795-805 
(2014). 
159. Helbig, I., Heinzen, E.L., Mefford, H.C. & the, I.G.C. Primer Part 1—The building blocks of 
epilepsy genetics. Epilepsia 57, 861-868 (2016). 
160. El Achkar, C.M., Olson, H.E., Poduri, A. & Pearl, P.L. The Genetics of the Epilepsies. 
Current Neurology and Neuroscience Reports 15, 39 (2015). 
  71 
161. InternationalLeagueAgainstEpilepsyConsortiumonComplexEpilepsies. Genetic determinants 
of common epilepsies: a meta-analysis of genome-wide association studies. Lancet Neurol 13, 
893-903 (2014). 
162. Hesdorffer, D.C. et al. ADHD as a risk factor for incident unprovoked seizures and epilepsy 
in children. Arch Gen Psychiatry 61, 731-6 (2004). 
163. Hermann, B. et al. The frequency, complications and aetiology of ADHD in new onset 
paediatric epilepsy. Brain 130, 3135-48 (2007). 
164. Hesdorffer, D.C., Caplan, R. & Berg, A.T. Familial clustering of epilepsy and behavioral 
disorders: evidence for a shared genetic basis. Epilepsia 53, 301-7 (2012). 
165. Halmoy, A., Klungsoyr, K., Skjaerven, R. & Haavik, J. Pre- and perinatal risk factors in 
adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 71, 474-81 (2012). 
166. Hawi, Z. et al. The molecular genetic architecture of attention deficit hyperactivity disorder. 
Mol Psychiatry 20, 289-297 (2015). 
167. Kaufmann, R., Goldberg-Stern, H. & Shuper, A. Attention-deficit disorders and epilepsy in 
childhood: incidence, causative relations and treatment possibilities. J Child Neurol 24, 727-
33 (2009). 
168. Ravi, M. & Ickowicz, A. Epilepsy, Attention-Deficit/Hyperactivity Disorder and 
Methylphenidate: Critical Examination of Guiding Evidence. Journal of the Canadian 
Academy of Child and Adolescent Psychiatry 25, 50 (2016). 
169. Gucuyener, K. et al. Use of methylphenidate for attention-deficit hyperactivity disorder in 
patients with epilepsy or electroencephalographic abnormalities. J Child Neurol 18, 109-12 
(2003). 
170. Rheims, S. et al. ADHD in childhood epilepsy: Clinical determinants of severity and of the 
response to methylphenidate. Epilepsia 57, 1069-77 (2016). 
171. van der Feltz-Cornelis, C.M. & Aldenkamp, A.P. Effectiveness and safety of methylphenidate 
in adult attention deficit hyperactivity disorder in patients with epilepsy: an open treatment 
trial. Epilepsy Behav 8, 659-62 (2006). 
172. Feldman, H., Crumrine, P., Handen, B.L., Alvin, R. & Teodori, J. Methylphenidate in 
children with seizures and attention-deficit disorder. Am J Dis Child 143, 1081-6 (1989). 
173. Adams, J. et al. Methylphenidate, cognition, and epilepsy: A double-blind, placebo-
controlled, single-dose study. Neurology 88, 470-476 (2017). 
174. Hemmer, S.A., Pasternak, J.F., Zecker, S.G. & Trommer, B.L. Stimulant therapy and seizure 
risk in children with ADHD. Pediatr Neurol 24, 99-102 (2001). 
175. Gonzalez-Heydrich, J. et al. ADAPTIVE PHASE-I STUDY OF OROS-
METHYLPHENIDATE TREATMENT OF ADHD WITH EPILEPSY. Epilepsy & behavior 
: E&B 18, 229-237 (2010). 
176. Gross-Tsur, V., Manor, O., van der Meere, J., Joseph, A. & Shalev, R.S. Epilepsy and 
attention deficit hyperactivity disorder: is methylphenidate safe and effective? J Pediatr 130, 
670-4 (1997). 
177. Santos, K. et al. The impact of methylphenidate on seizure frequency and severity in children 
with attention‐deficit–hyperactivity disorder and difficult‐to‐treat epilepsies. Developmental 
Medicine & Child Neurology 55, 654-660 (2013). 
178. Wroblewski, B.A., Leary, J.M., Phelan, A.M., Whyte, J. & Manning, K. Methylphenidate and 
seizure frequency in brain injured patients with seizure disorders. J Clin Psychiatry 53, 86-9 
(1992). 
 72 
179. Wiggs, K.K. et al. Attention-deficit/hyperactivity disorder medication and seizures. 
Neurology (2018). 
180. Lichtenstein, P., Tuvblad, C., Larsson, H., & Carlstrom, E. The Swedish twin study of child 
and adolescent development: the TCHAD-study. Twin Research and Human Genetics 10, 67 
(2007). 
181. Tuvblad, C., Grann, M. & Lichtenstein, P. Heritability for adolescent antisocial behavior 
differs with socioeconomic status: gene-environment interaction. J Child Psychol Psychiatry 
47, 734-43 (2006). 
182. Achenbach, T. Manual for the Child Behavior Checklist/4-18 and 1991 profiles. Burlington: 
University of Vermont Department of Psychiatry, (1991). 
183. Achenbach, T. & Rescorla, L. Manual for the ASEBA adult forms & profiles. Burlington, VT: 
University of Vermont (2003). 
184. Achenbach, T.M. Manual for the youth self-report and 1991 profile, (Department of 
Psychiatry, University of Vermont Burlington, 1991). 
185. Chen, W.J., Faraone, S.V., Biederman, J. & Tsuang, M.T. Diagnostic accuracy of the Child 
Behavior Checklist scales for attention-deficit hyperactivity disorder: a receiver-operating 
characteristic analysis. Journal of consulting and clinical psychology 62, 1017 (1994). 
186. Hudziak, J.J., Copeland, W., Stanger, C. & Wadsworth, M. Screening for DSM-IV 
externalizing disorders with the Child Behavior Checklist: a receiver-operating characteristic 
analysis. J Child Psychol Psychiatry 45, 1299-307 (2004). 
187. Larsson, J.O., Lichtenstein, P., Fried, I., El-Sayed, E. & Rydelius, P.A. Parents' perception of 
mental development and behavioural problems in 8 to 9-year-old children. Acta Pædiatrica 
89, 1469-1473 (2000). 
188. Larsson, J.-O. et al. An Evaluation of a Short Questionnaire for Parents About Their School-
Aged Children's Global Maturity Level. Child Psychiatry and Human Development 33, 59-73 
(2002). 
189. Anckarsater, H. et al. The Child and Adolescent Twin Study in Sweden (CATSS). Twin Res 
Hum Genet 14, 495-508 (2011). 
190. Magnusson, P.K. et al. The Swedish Twin Registry: establishment of a biobank and other 
recent developments. Twin Res Hum Genet 16, 317-29 (2013). 
191. Hansson, S.L. et al. Psychiatric telephone interview with parents for screening of childhood 
autism-tics, attention-deficit hyperactivity disorder and other comorbidities (A-TAC): 
preliminary reliability and validity. Br J Psychiatry 187(2005). 
192. Larson, T. et al. The Autism - Tics, AD/HD and other Comorbidities inventory (A-TAC): 
further validation of a telephone interview for epidemiological research. BMC Psychiatry 10, 
1 (2010). 
193. Kerekes, N. et al. Oppositional defiant- and conduct disorder-like problems: 
neurodevelopmental predictors and genetic background in boys and girls, in a nationwide 
twin study. PeerJ 2, e359 (2014). 
194. Larson, T. et al. Predictive properties of the A-TAC inventory when screening for childhood-
onset neurodevelopmental problems in a population-based sample. BMC Psychiatry 13, 233 
(2013). 
195. Birmaher, B. et al. Psychometric Properties of the Screen for Child Anxiety Related 
Emotional Disorders (SCARED): A Replication Study. Journal of the American Academy of 
Child & Adolescent Psychiatry 38, 1230-1236 (1999). 
  73 
196. Birmaher, B. et al. The Screen for Child Anxiety Related Emotional Disorders (SCARED): 
scale construction and psychometric characteristics. J Am Acad Child Adolesc Psychiatry 36, 
545-53 (1997). 
197. Muris, P., Merckelbach, H., Mayer, B. & Prins, E. How serious are common childhood fears? 
Behav Res Ther 38, 217-28 (2000). 
198. Hale, W.W., 3rd, Raaijmakers, Q., Muris, P. & Meeus, W. Psychometric properties of the 
Screen for Child Anxiety Related Emotional Disorders (SCARED) in the general adolescent 
population. J Am Acad Child Adolesc Psychiatry 44, 283-90 (2005). 
199. Crocetti, E., Hale, W.W., Fermani, A., Raaijmakers, Q. & Meeus, W. Psychometric properties 
of the Screen for Child Anxiety Related Emotional Disorders (SCARED) in the general 
Italian adolescent population: A validation and a comparison between Italy and The 
Netherlands. Journal of Anxiety Disorders 23, 824-829 (2009). 
200. Angold, A., Costello, E. J., Messer, S. C., & Pickles, A.  . Development of a short 
questionnaire for use in epidemiological studies of depression in children and adolescents. 
International Journal of Methods in Psychiatric Research 5, 237-249 (1995). 
201. Thapar, A. & McGuffin, P. Validity of the shortened Mood and Feelings Questionnaire in a 
community sample of children and adolescents: a preliminary research note. Psychiatry Res 
81, 259-68 (1998). 
202. Rhew, I.C. et al. Criterion validity of the Short Mood and Feelings Questionnaire and one- 
and two-item depression screens in young adolescents. Child Adolesc Psychiatry Ment Health 
4, 8 (2010). 
203. Ludvigsson, J.F., Otterblad-Olausson, P., Pettersson, B.U. & Ekbom, A. The Swedish 
personal identity number: possibilities and pitfalls in healthcare and medical research. 
European journal of epidemiology 24, 659-667 (2009). 
204. Ludvigsson, J.F. et al. Registers of the Swedish total population and their use in medical 
research. Eur J Epidemiol (2016). 
205. Ekbom, A. The Swedish Multi-generation Register. Methods Mol Biol 675, 215-20 (2011). 
206. Cnattingius, S., Ericson, A., Gunnarskog, J. & Kallen, B. A quality study of a medical birth 
registry. Scand J Soc Med 18, 143-8 (1990). 
207. NationalBoardofHealthandWelfare. The Swedish Medical Birth Registry. A summary of 
content and quality. Report 2003-112-3. Vol. 2016 (Stockholm, Sweden, 2003). 
208. NationalBoardofHealthandWelfare. National Patient Register - Quality of coding 2010. 
Report 2010-6-27 (2010). 
209. Ludvigsson, J.F. et al. External review and validation of the Swedish national inpatient 
register. BMC Public Health 11, 450 (2011). 
210. Wettermark, B. et al. The new Swedish Prescribed Drug Register--opportunities for 
pharmacoepidemiological research and experience from the first six months. 
Pharmacoepidemiol Drug Saf 16, 726-35 (2007). 
211. Karlsson, L., Wettermark, B. & Tomson, T. Drug treatment in patients with newly diagnosed 
unprovoked seizures/epilepsy. Epilepsy Research 108, 902-908 (2014). 
212. McGuffin, P., Owen, M.J. & Gottesman, I.I. Psychiatric genetics and genomics, (Oxford 
University Press, 2004). 
213. Hudson, J.I. et al. A structural approach to the familial coaggregation of disorders. 
Epidemiology 19, 431-9 (2008). 
214. Plomin, R., DeFries, J.C., Knopik, V.S. & Neiderhiser, J. Behavioral genetics, (Worth 
Publishers, 2013). 
 74 
215. Keller, M.C., Medland, S.E. & Duncan, L.E. Are Extended Twin Family Designs Worth the 
Trouble? A Comparison of the Bias, Precision, and Accuracy of Parameters Estimated in Four 
Twin Family Models. Behavior Genetics 40, 377-393 (2010). 
216. Posthuma, D. & Boomsma, D.I. A note on the statistical power in extended twin designs. 
Behavior genetics 30, 147-158 (2000). 
217. Sandin, S. et al. The familial risk of autism. JAMA 311, 1770-1777 (2014). 
218. Hallas, J. & Pottegård, A. Use of self-controlled designs in pharmacoepidemiology. Journal 
of Internal Medicine 275, 581-589 (2014). 
219. Petersen, I., Douglas, I. & Whitaker, H. Self controlled case series methods: an alternative to 
standard epidemiological study designs. BMJ 354(2016). 
220. Maier, R.M., Visscher, P.M., Robinson, M.R. & Wray, N.R. Embracing polygenicity: a 
review of methods and tools for psychiatric genetics research. Psychological Medicine, 1-19 
(2017). 
221. Wray, N.R. et al. Research review: polygenic methods and their application to psychiatric 
traits. J Child Psychol Psychiatry 55(2014). 
222. Wray, N.R. et al. Pitfalls of predicting complex traits from SNPs. Nat Rev Genet 14, 507-515 
(2013). 
223. Bollen, K.A. & Long, J.S. Tests for structural equation models: introduction. Sociological 
Methods & Research 21, 123-131 (1992). 
224. Lei, P.-W. & Wu, Q. Introduction to Structural Equation Modeling: Issues and Practical 
Considerations. Educational Measurement: Issues and Practice 26, 33-43 (2007). 
225. Neale, M.C., Eaves, L.J. & Kendler, K.S. The power of the classical twin study to resolve 
variation in threshold traits. Behav Genet 24, 239-58 (1994). 
226. Neale, M.C. et al. OpenMx 2.0: Extended Structural Equation and Statistical Modeling. 
Psychometrika, 1-15 (2015). 
227. Loehlin, J.C. The Cholesky approach: A cautionary note. Behavior Genetics 26, 65-69 
(1996). 
228. Rijsdijk, F.V. & Sham, P.C. Analytic approaches to twin data using structural equation 
models. Briefings in bioinformatics 3, 119-133 (2002). 
229. Muthén, L. & Muthén, B. Mplus 7.3. Muthén, Muthén 3463(2014). 
230. Schwarz, G. Estimating the dimension of a model. The annals of statistics 6, 461-464 (1978). 
231. Markon, K.E. & Krueger, R.F. An empirical comparison of information-theoretic selection 
criteria for multivariate behavior genetic models. Behav Genet 34, 593-610 (2004). 
232. Hu, L.t. & Bentler, P.M. Cutoff criteria for fit indexes in covariance structure analysis: 
Conventional criteria versus new alternatives. Structural Equation Modeling: A 
Multidisciplinary Journal 6, 1-55 (1999). 
233. Clayton, D., Hills, M. & Pickles, A. Statistical models in epidemiology, (Oxford university 
press Oxford, 1993). 
234. Efron, B. & Tibshirani, R. Bootstrap methods for standard errors, confidence intervals, and 
other measures of statistical accuracy. Statistical science, 54-75 (1986). 
235. Williams, R.L. A note on robust variance estimation for cluster‐correlated data. Biometrics 
56, 645-646 (2000). 
236. Armstrong, B.G., Gasparrini, A. & Tobias, A. Conditional Poisson models: a flexible 
alternative to conditional logistic case cross-over analysis. BMC Med Res Methodol 14(2014). 
  75 
237. Kendler, K.S. et al. A longitudinal twin study of fears from middle childhood to early 
adulthood: evidence for a developmentally dynamic genome. Arch Gen Psychiatry 65, 421-9 
(2008). 
238. Rietveld, C.A. et al. GWAS of 126,559 individuals identifies genetic variants associated with 
educational attainment. Science 340, 1467-71 (2013). 
239. Purcell, S. et al. PLINK: A Tool Set for Whole-Genome Association and Population-Based 
Linkage Analyses. The American Journal of Human Genetics 81, 559-575 (2007). 
240. StatisticsSweden. Different families live in different ways – a survey on residence and support 
of children after a separation. (2014). 
241. Pottegard, A., Hallas, J., Hernandez, D. & Zoega, H. Children's relative age in class and use 
of medication for ADHD: a Danish Nationwide Study. J Child Psychol Psychiatry 55, 1244-
50 (2014). 
242. Dalsgaard, S., Humlum, M.K., Nielsen, H.S. & Simonsen, M. Relative standards in ADHD 
diagnoses: The role of specialist behavior. Economics Letters 117, 663-665 (2012). 
243. Neumann, A. et al. Single Nucleotide Polymorphism Heritability of a General 
Psychopathology Factor in Children. Journal of the American Academy of Child & 
Adolescent Psychiatry 55, 1038-1045.e4 (2016). 
244. Alnæs, D., Kaufmann, T., Doan, N. & et al. Association of heritable cognitive ability and 
psychopathology with white matter properties in children and adolescents. JAMA Psychiatry 
75, 287-295 (2018). 
245. Smoller, J.W. et al. Psychiatric genetics and the structure of psychopathology. Mol Psychiatry 
(2018). 
246. Dudbridge, F., Pashayan, N. & Yang, J. Predictive accuracy of combined genetic and 
environmental risk scores. Genetic Epidemiology 42, 4-19 (2018). 
247. Bromley, R. The treatment of epilepsy in pregnancy: The neurodevelopmental risks 
associated with exposure to antiepileptic drugs. Reproductive Toxicology 64, 203-210 (2016). 
248. Nielsen, P.R., Benros, M.E. & Dalsgaard, S. Associations Between Autoimmune Diseases 
and Attention-Deficit/Hyperactivity Disorder: A Nationwide Study. J Am Acad Child Adolesc 
Psychiatry 56, 234-240.e1 (2017). 
249. Keret, A. et al. Posttraumatic epilepsy: long-term follow-up of children with mild traumatic 
brain injury. Journal of Neurosurgery: Pediatrics 20, 64-70 (2017). 
250. Sun, Y. et al. Gestational age, birth weight, intrauterine growth, and the risk of epilepsy. Am J 
Epidemiol 167, 262-70 (2008). 
251. D’Onofrio, B.M. et al. Preterm birth and mortality and morbidity: A population-based quasi-
experimental study. JAMA Psychiatry 70, 1231-1240 (2013). 
252. Rom, A.L. et al. Parental rheumatoid arthritis and childhood epilepsy: A nationwide cohort 
study. Neurology 87, 2510-2516 (2016). 
253. Tylee, D.S. et al. Genetic correlations among psychiatric and immune-related phenotypes 
based on genome-wide association data. bioRxiv (2018). 
254. Besag, F. et al. Psychiatric and Behavioural Disorders in Children with Epilepsy (ILAE Task 
Force Report): When should pharmacotherapy for psychiatric/behavioural disorders in 
children with epilepsy be prescribed? Epileptic Disorders 18, S77-S86 (2016). 
255. Williams, A.E., Giust, J.M., Kronenberger, W.G. & Dunn, D.W. Epilepsy and attention-
deficit hyperactivity disorder: links, risks, and challenges. Neuropsychiatric Disease and 
Treatment 12, 287-296 (2016). 
 76 
256. Du Rietz, E. et al. Predictive validity of parent- and self-rated ADHD symptoms in 
adolescence on adverse socioeconomic and health outcomes. Eur Child Adolesc Psychiatry 
26, 857-867 (2017). 
257. Johnson, S.A., Filliter, J.H. & Murphy, R.R. Discrepancies Between Self- and Parent-
Perceptions of Autistic Traits and Empathy in High Functioning Children and Adolescents on 
the Autism Spectrum. Journal of Autism and Developmental Disorders 39, 1706-1714 (2009). 
258. Cosi, S., Canals, J., Hernández-Martinez, C. & Vigil-Colet, A. Parent–child agreement in 
SCARED and its relationship to anxiety symptoms. Journal of Anxiety Disorders 24, 129-133 
(2010). 
259. Bartels, M., Boomsma, D.I., Hudziak, J.J., van Beijsterveldt, T.C. & van den Oord, E.J. 
Twins and the study of rater (dis)agreement. Psychol Methods 12, 451-66 (2007). 
260. Hartman, C., Rhee, S., Willcutt, E. & Pennington, B. Modeling Rater Disagreement for 
ADHD: Are Parents or Teachers Biased? Journal of Abnormal Child Psychology 35, 536-542 
(2007). 
261. Freitag, C.M., Rohde, L.A., Lempp, T. & Romanos, M. Phenotypic and measurement 
influences on heritability estimates in childhood ADHD. Eur Child Adolesc Psychiatry 19, 
311-23 (2010). 
262. Derks, E.M., Dolan, C.V. & Boomsma, D.I. A test of the equal environment assumption 
(EEA) in multivariate twin studies. Twin Research and Human Genetics 9, 403-411 (2006). 
263. Nordsletten, A.E. et al. Patterns of nonrandom mating within and across 11 major psychiatric 
disorders. JAMA Psychiatry 73, 354-361 (2016). 
264. Turley, P. et al. Multi-trait analysis of genome-wide association summary statistics using 
MTAG. Nature Genetics (2018). 
265. Boyle, E.A., Li, Y.I. & Pritchard, J.K. An Expanded View of Complex Traits: From 
Polygenic to Omnigenic. Cell 169, 1177-1186 (2017). 
266. Huybrechts, K.F. et al. Association Between Methylphenidate and Amphetamine Use in 
Pregnancy and Risk of Congenital Malformations: A Cohort Study From the International 
Pregnancy Safety Study Consortium. JAMA Psychiatry 75, 167-175 (2018). 
267. Guxens, M. et al. Air Pollution Exposure during Pregnancy and Childhood Autistic Traits in 
Four European Population-Based Cohort Studies: The ESCAPE Project. Environ Health 
Perspect 124, 133-40 (2016). 
 
